0001493152-23-040961.txt : 20231114 0001493152-23-040961.hdr.sgml : 20231114 20231114143529 ACCESSION NUMBER: 0001493152-23-040961 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 32 CONFORMED PERIOD OF REPORT: 20230930 FILED AS OF DATE: 20231114 DATE AS OF CHANGE: 20231114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GlucoTrack, Inc. CENTRAL INDEX KEY: 0001506983 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 980668934 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-41141 FILM NUMBER: 231404532 BUSINESS ADDRESS: STREET 1: 301 RT 17 NORTH STREET 2: SUITE 800 CITY: RUTHERFORD STATE: NJ ZIP: 07070 BUSINESS PHONE: 972 (8) 675-7878 MAIL ADDRESS: STREET 1: 301 RT 17 NORTH STREET 2: SUITE 800 CITY: RUTHERFORD STATE: NJ ZIP: 07070 FORMER COMPANY: FORMER CONFORMED NAME: Integrity Applications, Inc. DATE OF NAME CHANGE: 20101203 10-Q 1 form10-q.htm
false Q3 --12-31 0001506983 0001506983 2023-01-01 2023-09-30 0001506983 2023-11-14 0001506983 2023-09-30 0001506983 2022-12-31 0001506983 2023-07-01 2023-09-30 0001506983 2022-07-01 2022-09-30 0001506983 2022-01-01 2022-09-30 0001506983 us-gaap:CommonStockMember 2022-12-31 0001506983 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001506983 GCTK:ReceiptsOnAccountOfSharesMember 2022-12-31 0001506983 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001506983 us-gaap:RetainedEarningsMember 2022-12-31 0001506983 us-gaap:CommonStockMember 2023-06-30 0001506983 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001506983 GCTK:ReceiptsOnAccountOfSharesMember 2023-06-30 0001506983 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001506983 us-gaap:RetainedEarningsMember 2023-06-30 0001506983 2023-06-30 0001506983 us-gaap:CommonStockMember 2021-12-31 0001506983 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001506983 GCTK:ReceiptsOnAccountOfSharesMember 2021-12-31 0001506983 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001506983 us-gaap:RetainedEarningsMember 2021-12-31 0001506983 2021-12-31 0001506983 us-gaap:CommonStockMember 2022-06-30 0001506983 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001506983 GCTK:ReceiptsOnAccountOfSharesMember 2022-06-30 0001506983 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001506983 us-gaap:RetainedEarningsMember 2022-06-30 0001506983 2022-06-30 0001506983 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001506983 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-09-30 0001506983 GCTK:ReceiptsOnAccountOfSharesMember 2023-01-01 2023-09-30 0001506983 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-09-30 0001506983 us-gaap:RetainedEarningsMember 2023-01-01 2023-09-30 0001506983 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001506983 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001506983 GCTK:ReceiptsOnAccountOfSharesMember 2023-07-01 2023-09-30 0001506983 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001506983 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001506983 us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001506983 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-09-30 0001506983 GCTK:ReceiptsOnAccountOfSharesMember 2022-01-01 2022-09-30 0001506983 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-09-30 0001506983 us-gaap:RetainedEarningsMember 2022-01-01 2022-09-30 0001506983 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001506983 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001506983 GCTK:ReceiptsOnAccountOfSharesMember 2022-07-01 2022-09-30 0001506983 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0001506983 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001506983 us-gaap:CommonStockMember 2023-09-30 0001506983 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001506983 GCTK:ReceiptsOnAccountOfSharesMember 2023-09-30 0001506983 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001506983 us-gaap:RetainedEarningsMember 2023-09-30 0001506983 us-gaap:CommonStockMember 2022-09-30 0001506983 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001506983 GCTK:ReceiptsOnAccountOfSharesMember 2022-09-30 0001506983 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0001506983 us-gaap:RetainedEarningsMember 2022-09-30 0001506983 2022-09-30 0001506983 GCTK:PrefundedWarrantsMember 2023-07-01 2023-09-30 0001506983 GCTK:PrefundedWarrantsMember 2022-07-01 2022-09-30 0001506983 GCTK:PrefundedWarrantsMember 2023-01-01 2023-09-30 0001506983 GCTK:PrefundedWarrantsMember 2022-01-01 2022-09-30 0001506983 2023-04-13 2023-04-13 0001506983 us-gaap:CommonStockMember 2023-04-13 2023-04-13 0001506983 GCTK:PrefundedWarrantsMember 2023-04-13 2023-04-13 0001506983 GCTK:PrefundedWarrantsMember 2023-04-13 0001506983 srt:MinimumMember 2023-04-13 0001506983 srt:MaximumMember 2023-04-13 0001506983 2023-04-13 0001506983 GCTK:IntellectualPropertyPurchaseAgreementMember 2023-01-01 2023-09-30 0001506983 GCTK:IntellectualPropertyPurchaseAgreementMember 2023-07-01 2023-09-30 0001506983 2023-05-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
   
  For the quarterly period ended September 30, 2023

 

or

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
   
  For the transition period from ________________ to ________________

 

Commission File Number: 001-41141

 

GLUCOTRACK, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   98-0668934

(State or other jurisdiction of

incorporation or organization)

  

(I.R.S. Employer

Identification No.)

     

301 Route 17 North, Suite 800

Rutherford, NJ

   07070
(Address of principal executive offices)   (Zip Code)

 

(201) 842-7715

(Registrant’s telephone number, including area code)

 

N/A

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock   GCTK   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

  Large accelerated filer ☐   Accelerated filer ☐
  Non-accelerated filer ☒   Smaller reporting company ☒
  Emerging growth company ☐    

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

As of November 14, 2023, 20,892,193 shares of the Company’s common stock, par value $0.001 per share, were outstanding.

 

 

 

 
 

 

GLUCOTRACK INC.

 

TABLE OF CONTENTS

 

  Page
PART I - FINANCIAL INFORMATION 4
Item 1. Financial Statements. 4
Condensed Consolidated Balance Sheets 4
Condensed Consolidated Statements of Operations and Comprehensive Loss 5
Condensed Consolidated Statement of Changes in Stockholders’ Equity 6
Condensed Consolidated Statements of Cash Flows 7
Notes to Condensed Consolidated Financial Statements 8
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations. 11
Item 3. Quantitative and Qualitative Disclosures About Market Risk. 16
Item 4. Controls and Procedures. 16
PART II - OTHER INFORMATION 17
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 17
Item 6. Exhibits. 17
EXHIBIT INDEX 17
SIGNATURES 18

 

2

 

 

CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS

 

This Quarterly Report on Form 10-Q includes forward-looking statements. These forward-looking statements include statements about our expectations, beliefs or intentions regarding our product development efforts, business, financial condition, results of operations, strategies or prospects. All statements other than statements of historical fact included in this Quarterly Report on Form 10-Q, including statements regarding our future activities, events or developments, including such things as future revenues, product development, clinical trials, regulatory approval, market acceptance, responses from competitors, capital expenditures (including the amount and nature thereof), business strategy and measures to implement strategy, competitive strengths, goals, expansion and growth of our business and operations, plans, references to future success, projected performance and trends, and other such matters, are forward-looking statements. The words “believe,” “expect,” “intend,” “anticipate,” “estimate,” “plan,” “may,” “will,” “could,” “would,” “should” and other similar words and phrases or the negative of such terms, are intended to identify forward-looking statements. The forward-looking statements made in this Quarterly Report on Form 10-Q are based on certain historical trends, current conditions and expected future developments, as well as other factors we believe are appropriate in the circumstances. These statements relate only to events as of the date on which the statements are made and we undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. All of the forward-looking statements made in this Quarterly Report on Form 10-Q are qualified by these cautionary statements and there can be no assurance that the actual results anticipated by us will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Whether actual results will conform to our expectations and predictions is subject to a number of risks and uncertainties that may cause actual results to differ materially. Risks and uncertainties, the occurrence of which could adversely affect our business, include the risks identified in our Annual Report on Form 10-K for year ended December 31, 2022, under the caption “Risk Factors.” We undertake no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances that may arise after the date of this report unless required by law.

 

3

 

 

GLUCOTRACK INC.

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

 

GLUCOTRACK INC.

 

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands of US dollars except share data)

 

  

September 30,

2023

   December 31,
2022		 
   (Unaudited)     
Current assets          
Cash and cash equivalents  $6,888   $2,312 
Other current assets   281    67 
Total current assets   7,169    2,379 
           
Property and equipment, net   17    40 
Restricted cash   9    19 
TOTAL ASSETS   7,195    2,438 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current liabilities          
Accounts payable   1,249    672 
Other current liabilities   205    341 
Total current liabilities  $1,454   $1,013 
           
Non-current liabilities          
Loans from stockholders   184    195 
Total non-current liabilities   184    195 
Total liabilities   1,638    1,208 
           
Stockholders’ equity          
Common Stock of $ 0.001 par value (“Common Stock”):          
500,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 20,892,193 and 15,500,730 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively   20    15 
           
Additional paid-in capital   112,944    103,095 
Accumulated other comprehensive income   34    17 
Receipts on account of shares   -    4 
Accumulated deficit   (107,441)   (101,901)
Total stockholders’ equity   5,557    1,230 
           
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY  $7,195   $2,438 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

4

 

 

GLUCOTRACK INC.

 

 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(in thousands of US dollars except share data) (unaudited)

 

                     
  

Three-month

period ended September 30,

  

Nine-month

period ended September 30,

 
   2023   2022   2023   2022 
                 
Research and development  $1,693   $434   $2,962   $1,363 
General and administrative   531    495    1,725    1,782 
Total operating expenses   2,224    929    4,687    3,145 
                     
Operating loss   2,224    929    4,687    3,145 
                     
Other expenses   -    1    -    1 
                     
Finance expenses (income), net   (1)   (2)   (2)   2
                     
Net Loss   2,223    928    

4,685

    3,148 
Other comprehensive income:                    
Foreign currency translation adjustment   (6)   (1)   (17)   (36)
                     
Comprehensive loss for the period  $2,217   $929   $4,668   $3,112 
                     
Basic and diluted net loss per common stock  $(0.10)  $(0.06)  $(0.28)  $(0.20)
                     
Weighted average number of common stock used in computing basic and diluted loss per common stock   22,968,663    15,473,521    20,032,634    15,468,279 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

5

 

 

GLUCOTRACK INC.

 

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY

(in thousands of US Dollars except share data) (unaudited)

 

   Numbers
of Shares		   Amount   Paid-in
Capital		   of
shares		   Comprehensive
Income (Loss)		   Accumulated
Deficit		  

Stockholders’
Equity

 
   Common Stock   Additional   Receipts
on
account		   Accumulated
Other		       Total 
   Numbers
of Shares		   Amount   Paid-in
Capital		   of
shares		   Comprehensive
Income (Loss)		   Accumulated
Deficit		  

Stockholders’
Equity

 
                             
Balance at January 1, 2023   15,500,730   $15   $103,095   $4   $17   $(101,901)  $1,230 
Loss for the period   -    -    -    -    -    (4,685)   (4,685)
Other comprehensive income   -    -    -    -    17    -    17 
Deemed dividend resulted from trigger of down round protection feature of certain warrants granted   -    -    855    -    -    (855)   - 
Net proceeds received from underwritten U.S. public offering   5,376,472    5    8,725    -    -    -    8,730 
Issuance of restricted shares as compensation towards directors and officer   14,991    -(*)-    9    (4)   -    -    5 
Stock-based compensation   -    -    260    -    -    -    260 
Balance at September 30, 2023   20,892,193   $20   $112,944   $-   $34   $(107,441)  $5,557 
                                    
Balance at July 1, 2023   20,892,193   $20   $112,913   $-   $28   $(105,218)  $7,743 
Loss for the period   -    -    -    -    -    (2,223)   (2,223)
Other comprehensive income   -    -    -    -    6    -    6 
Stock-based compensation   -    -    31    -    -    -    31 
Balance at September 30, 2023   20,892,193   $20   $112,944   $-   $34   $(107,441)  $5,557 
                                    
Balance at January 1, 2022   15,452,285   $15   $102,612   $-   $(6)  $(97,466)  $5,155 
Loss for the period   -    -    -    -    -    (3,148)   (3,148)
Other comprehensive income   -    -    -    -    36    -    36 
Issuance of restricted shares as compensation towards directors   11,275    -    20    -    -    -    20 
Restricted shares to be issued as compensation towards directors   -    -(*)-    -    18    -    -    18 
Stock-based compensation   13,105    -    274    -    -    -    274 
Balance at September 30, 2022   15,476,665   $15   $102,906   $18   $30   $(100,614)  $2,355 
                                    
Balance at July 1, 2022   15,473,262   $15   $102,821   $9   $31   $(99,686)  $3,190 
                                    
Loss for the period   -    -    -    -    -    (928)   (928)
Other comprehensive income   -    -    -    -    (1)   -    (1)
Issuance of restricted shares as compensation towards directors   3,403    -(*)-    9    (9)   -    -    - 
Restricted shares to be issued as compensation towards directors   -    -    -    18    -    -    18 
Stock-based compensation   -    -    76    -    -    -    76 
Balance at September 30, 2022   15,476,665   $15   $102,906   $18   $30   $(100,614)  $2,355 

 

(*) Represents amount lower than $1.

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

6

 

 

GLUCOTRACK INC.

 

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands of US Dollars)

 

   2023   2022 
   Nine-month period ended September 30, 
   2023   2022 
   (Unaudited) 
CASH FLOWS FROM OPERATING ACTIVITIES          
Loss for the period  $(4,685)  $(3,148)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation   21    19 
Stock-based compensation   260    274 
Issuance of restricted shares as compensation towards directors   5    38 
Linkage difference on principal of loans from stockholders   4    8 
Changes in assets and liabilities:          
Increase in other current assets   (216)   (148)
Increase in accounts payable   598    117 
Increase (Decrease) in other current liabilities   (134)   51 
Net cash used in operating activities   (4,147)   (2,789)
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
Purchase of property and equipment   -    (4)
Net cash used in investing activities   -    (4)
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Net proceeds received from underwritten U.S. public offering   8,730    - 
Net cash provided by financing activities   8,730    - 
           
Effect of exchange rate changes on cash and cash equivalents, and restricted cash   (17)   (40)
           
Change in cash, cash equivalents, and restricted cash   4,566    (2,833)
           
Cash, cash equivalents, and restricted cash at beginning of the period   2,331    6,113 
           
Cash, cash equivalents, and restricted cash, end of period  $6,897   $3,280 
           
Non-cash financing activities          
Deemed dividend upon trigger of down round protection  $855   $- 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

7

 

 

GLUCOTRACK INC.

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

 

NOTE 1 – GENERAL

 

A. GlucoTrack Inc. (the “Company”) was incorporated on May 18, 2010 under the laws of the State of Delaware. The Company is a medical device company, focused on the design, development and commercialization of novel technologies for use by people with diabetes. The Company is currently developing an Implantable Continuous Glucose Monitor (CGM) for persons with Type 1 diabetes and insulin-dependent Type 2 diabetes.
   
B. Liquidity and capital resources
   
  To date, the Company has not yet generated significant revenues from GlucoTrack product, a non-invasive spot measurement glucose sensor that has been discontinued. In addition, development and commercialization of the Implantable CGM is expected to require substantial expenditures; therefore, the Company is dependent upon external sources for financing its operations. As of September 30, 2023, the Company has incurred accumulated deficit of $107,441 thousand. Furthermore, the Company has generated operating losses and negative operating cash flow for all reported periods.
   
  Management has considered the significance of such conditions in relation to the Company’s ability to meet its current obligations and to achieve its business targets and determined that these conditions do not raise substantial doubt about the Company’s ability to continue as a going concern, taking into consideration the net proceeds received in total amount of $8,730 thousand upon closing of a public offering through prospectus supplement on Form S-3 on April 17, 2023 (see also Note 3A below). As of September 30, 2023, our cash on hand will provide sufficient working capital to fund its current operations and animal trial program for the development of its Implantable CGM for a period of twelve-months subsequent to the reporting period.

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

A. Basis of Presentation

 

  1. Accounting Principles
     
    The accompanying unaudited condensed consolidated interim financial statements and related notes should be read in conjunction with the consolidated financial statements and related notes contained in the Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the Securities and Exchange Commission (“SEC”) on March 31, 2023. The unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC related to interim financial statements. As permitted under those rules, certain information and footnote disclosures normally required or included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The financial information contained herein is unaudited; however, management believes all adjustments have been made that are considered necessary to present fairly the results of the Company’s financial position and operating results for the interim periods. All such adjustments are of a normal recurring nature.
     
    The results for the period of nine months ended September 30, 2023 are not necessarily indicative of the results to be expected for the year ending December 31, 2023 or for any other interim period or for any future period.
     
  2. Principles of Consolidation
     
    The consolidated financial statements include the accounts of the Company and its subsidiary. Significant intercompany balances and transactions have been eliminated in consolidation.

 

8

 

 

GLUCOTRACK INC.

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)

 

A. Basis of Presentation

 

  3. Net Loss Per Common Stock
     
    Basic net loss per Common Stock is computed by dividing the loss for the period applicable for holders of Common Stock and pre-funded warrants (after considering the effect of deemed dividend related to trigger of down round protection feature) dividend by the weighted average number of outstanding shares of Common Stock and shares of Common Stock to be issued upon exercise of pre-funded warrants (see Note 3A below) or shares of Common Stock to be issued upon achievement of performance milestone (see Note 3B below) during the period. Diluted loss per share gives effect to all potentially dilutive common shares outstanding during the period using the treasury stock method with respect to stock options and certain stock warrants. In computing diluted loss per share, the average stock price for the period is used in determining the number of Common Stock assumed to be purchased from the exercise of stock options or stock warrants.
     
    Shares to be issued upon exercise of all stock options and stock warrants have been excluded from the calculation of the diluted net loss per Common Stock for all the reported periods for which net loss was reported because the effect of the Common Stock issuable upon exercise of these instruments was anti-dilutive.
     
    The net loss and the weighted average number of shares of Common Stock used in computing basic and diluted net loss per share for the period of three and nine months ended September 30, 2023 and 2022, is as follows:

 

   2023   2022   2023   2022 
     US dollars in thousands
(except share data)		    

US dollars in thousands

(except share data)

 
    

Three-month period

ended
September 30,

    

Nine-month period

ended
September 30,

 
     (Unaudited)     (Unaudited) 
     2023       2022     2023   2022 
                         
Numerator:                          
Net loss  $ 2,223     $ 928     $4,685   $3,148 
Deemed dividend related to trigger of down round protection feature (see Note 3A below)    -       -      855    - 
Net loss attributable to common stockholders  $ 2,223     $ 928     $5,540   $3,148 
                           
Denominator:                          
Shares of Common Stock used in computing basic and diluted net loss per common stock    20,892,193       15,473,521      18,792,950    15,468,279 
Shares of Common Stock to be issued upon exercise of pre-funded warrants    -       1,976,470      1,206,228    - 
Shares of Common Stock to be issued upon achievement of performance milestone            100,000      33,456      
Basic and diluted net loss per common stock  $ (0.10 )   $ (0.06 )   $(0.28)  $(0.2)

 

9

 

 

GLUCOTRACK INC.

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONT.)

 

NOTE 3 - SIGNIFICANT TRANSACTIONS

 

A. Completion of underwritten U.S. public offering
   
  On April 13, 2023, the Company completed an underwritten public offering under which the Company received gross proceeds of approximately $10 million for issuance of (i) 5,376,472 shares of common stock and (ii) 1,976,470 pre-funded warrants at a price to the public of $1.36 per share. The pre-funded warrants are exercisable for the same number of shares of common stock and may be exercised at any time until exercised in full at an exercise price of $0.001.
   
  Upon satisfaction of customary closing conditions, the closing date of the above underwritten public offering was April 17, 2023 (the “Closing Date”).
   
  The Company received substantially all the pre-funded warrant’s proceeds upfront (without any conditions) as part of the pre-funded warrant’s purchase price and in return the Company is obligated to issue fixed number of shares of common stock to the holders. Thus, pre-funded warrants were accounted for and were classified as additional paid-in capital as part of the Company’s stockholders’ equity.
   
  Total incremental and direct issuance costs amounted to $1,270 thousand. These expenses were deducted from additional paid-in capital as they were allocated to shares of Common Stock and pre-funded warrants.

 

  Upon closing of underwritten U.S. public offering, a down round protection feature of certain warrants granted in previous years to service providers was triggered by the way of reduction of their exercise price from a price in a range of $3.35-$70.20 to a price of $1.36 which represented the above public offering price. Such reduction was accounted for as deemed dividend estimated at total amount of $855 thousand which was recorded as part of the additional paid-in capital versus increase of accumulated deficit. Regarding the effect of the loss per share, see also Note 2.A.3. above.

 

B. Intellectual Property Purchase Agreement 
   
  In the middle of June 2023, the Company achieved the first performance milestone out of the five performance milestones outlined in the Intellectual Property Purchase Agreement (the “Agreement”) executed between the Company and Paul Goode, which is the Company’s Chief Executive Officer (the “Seller”) as October 7, 2022 (the “Closing Date”). As a result, upon the date of fulfillment of the performance milestone the Company is committed to issue 100,000 restricted shares to the Seller. During the periods of three and nine months ended September 30, 2023, the Company recorded stock-based compensation expenses of $0 and $131 thousand, respectively, which represents the quoted price of its Common Stock at the Closing Date, after taking into consideration a discount for lack of marketability at a rate of 30.4% over a restriction period of 1-year. As of September 30, 2023, achievement of all other performance milestones was not considered probable and thus no stock-based compensation expenses were recorded with respect to thereof.
   
C. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
   
  On May 26, 2023, the Company received a letter from Nasdaq that it no longer complies with Rule 5550(a)(2) of Nasdaq’s Listing Rules (the “Rules”) which require listed securities to maintain a minimum bid price of $1 per share. However, the Rules provide the Company a compliance period of 180-days to regain compliance under which if at any time during 180-days period the closing bid price of the Company’s security is at least $1 for a minimum of ten consecutive business days, Nasdaq will provide the Company written confirmation of compliance and this matter will be closed. In the event the Company does not regain compliance by the 180th day, the Company may be eligible for additional time to regain compliance or may face delisting.

 

NOTE 4 - SUBSEQUENT EVENTS

 

The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the condensed interim consolidated financial statements were issued November 14, 2023. Based upon this review, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements.

 

10

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

Cautionary Note Regarding Forward-Looking Statements

 

This Quarterly Report on Form 10-Q contains forward-looking statements. These forward-looking statements include statements about our expectations, beliefs or intentions regarding our product development efforts, business, financial condition, results of operations, strategies and prospects. All statements other than statements of historical fact included in this Quarterly Report on Form 10-Q, including statements regarding our future activities, events or developments, including such things as future revenues, capital raising and financing, product development, clinical trials, regulatory approval, market acceptance, responses from competitors, capital expenditures (including the amount and nature thereof), business strategy and measures to implement strategy, competitive strengths, goals, expansion and growth of our business and operations, plans, references to future success, projected performance and trends, and other such matters, are forward-looking statements. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “plan,” “may,” “will,” “could,” “would,” “should” and other similar words and phrases, are intended to identify forward-looking statements. The forward-looking statements made in this Quarterly Report on Form 10-Q are based on certain historical trends, current conditions and expected future developments as well as other factors we believe are appropriate in the circumstances. These statements relate only to events as of the date on which the statements are made and we undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. All of the forward-looking statements made in this Quarterly Report on Form 10-Q are qualified by these cautionary statements and there can be no assurance that the actual results anticipated by us will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Whether actual results will conform to our expectations and predictions is subject to a number of risks and uncertainties that may cause actual results to differ materially. Risks and uncertainties, the occurrence of which could adversely affect our business, include the risks identified under the caption “Risk Factors” included in our annual report on Form 10-K for the year ended December 31, 2022. The following discussion should be read in conjunction with the condensed consolidated financial statements and the notes thereto included in Item 1 of this Quarterly Report on Form 10-Q.

 

Overview

 

We are a medical device company focused on the design, development and commercialization of novel technologies for use by people with diabetes. We are currently developing an Implantable (CGM) for those with Type 1 diabetes and insulin-dependent Type 2 diabetes.

 

The Company was founded with a mission to develop GlucoTrack®, a noninvasive glucose monitoring device designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain, inconvenience, cost and difficulty of conventional (invasive) spot finger stick devices. The first generation GlucoTrack, which successfully received CE Mark approval, obtained glucose measurements via a small sensor clipped onto one’s earlobe. A limited release beta test in Europe and the Middle East demonstrated the need for an updated product with improved accuracy and human factors. As the glucose monitoring landscape rapidly moved away from point-in-time measurement to continuous measurement since then, the Company recently determined that it would focus its efforts on developing its Implantable CGM. As such, we have since withdrawn our CE Mark for GlucoTrack and are no longer pursuing commercialization of this product or development of any further iterations.

 

11

 

 

The Company is currently developing an Implantable CGM for use by Type 1 diabetes patients as well as insulin-dependent Type 2 patients. Implant longevity is key to the success of such a device. We have recently completed a feasibility study successfully demonstrating that a minimum two-year implant life is highly probable with the current sensor design. We have also initiated an animal study with an initial prototype system that has thus far demonstrated a simple implant procedure and good functionality. The Company will initiate a long-term animal trial in late Q4 as well as initiate development of its commercial device, also in late Q4, in preparation of regulatory submission in late 2024 for a first in human study. We believe our technology, if successful, has the potential to be more accurate, more convenient and have a longer duration than other implantable glucose monitors that are either in the market or currently under development.

 

We are currently developing our own mobile companion application and a cloud-based solution platform to provide real time, data driven personalized tools to effectively help a user manage their diabetes. In addition to being a critical and effective management tool for the end user, we believe that third parties such as insurers, pharmaceutical companies and advertisers would be willing to pay for the de-identified data that we will obtain through our platform, and that this is an opportunity for us to develop an additional revenue source.

 

Our Senior Management team includes; CEO and President, Paul V. Goode PhD, who has a decorated career developing innovative medical technologies, including at DexCom and MiniMed, CFO, James Cardwell, CPA who has over 16 years of experience as a Chief Financial Officer and Chief Operating Officer with a concentration in both SEC financial reporting and tax compliance, James P. Thrower PhD, Vice President of Engineering, a seasoned executive formerly of Sterling Medical Devices, Mindray DS USA and DexCom, Inc., Mark Tapsak PhD, Vice President of Sensor Technology, a medical research scientist who brings over 25 years of experience in the diabetes industry, including previous senior roles at DexCom and Medtronic, and Drinda Benjamin, Vice President of Marketing, a medical device professional with over 20 years of experience in the medical device and diabetes industry with senior roles at Intuity Medical, Senseionics, Abbott Diabetes, and Medtronic Diabetes. Erin Carter, formerly of Medtronic and Boston Scientific, has joined as an independent board member. Several highly talented and accomplished executives joined the Company as senior advisors to the Board. These include Daniel McCaffrey MBA MA, a world-renowned behavioral scientist and digital health expert formerly at Samsung Health and Dexcom, Inc., Dr. Alexander Raykhman PhD, a measurement and artificial intelligence expert and Dr. David C. Klonoff, world renowned endocrinologist and diabetes technology thought leader. We intend to continue to invest in our talent and to expand and strengthen all areas within the Company.

 

12

 

 

Recent Events

 

On April 13, 2023, the Company completed an underwritten public offering under which the Company received gross proceeds of approximately $10 million for issuance of (i) 5,376,472 shares of common stock and (ii) 1,976,470 pre-funded warrants at a price to the public of $1.36 per share. After completing this transaction, the Company regained compliance with NASDAQ regarding the notice it received on November 22, 2022.

 

On April 17, 2023, the Company announced the closing of a firm commitment underwritten public offering of shares of its common stock with gross proceeds to the Company of approximately $10 million, before deducting underwriting discounts and other estimated expenses. The offering consisted of 5,376,472 shares of common stock and 1,976,470 pre-funded warrants to purchase shares of common stock at a price to the public of $1.36 per share (less $0.001 in exercise price per pre-funded warrant). The Company entered into an underwriting agreement with Aegis Capital Corp. on April 13, 2023. The Company intends to use the net proceeds from this offering primarily for working capital and general corporate purposes, which may include, without limitation, engaging in acquisitions or other business combinations or investments, sales and marketing activities, general and administrative matters and capital expenditures.

 

On May 26, 2023, the Company received a letter from Nasdaq that it no longer complies with Rule 5550(a)(2) of Nasdaq’s Listing Rules (the “Rules”) which require listed securities to maintain a minimum bid price of $1 per share. However, the Rules also provide the Company a compliance period of 180 calendar days in which to regain compliance. Pursuant to Rule 5810(c)(3)(C) if at any time during this 180-day period the closing bid price of the Company’s security is at least $1 for a minimum of ten consecutive business days, Nasdaq will provide the Company written confirmation of compliance and this matter will be closed. In the event the Company does not regain compliance by the 180th day, the Company may be eligible for additional time to regain compliance or may face delisting.

 

On July 25, 2023, the Company announced the completion and positive results of its feasibility study for its implantable continuous glucose monitor technology for patients with Type 1 and Type 2 insulin-dependent diabetes. The primary goal of the feasibility study was to demonstrate that the CGM sensor design could reliably report glucose measurements for two years post-implant. Laboratory bench testing confirmed that a minimum two-year implant longevity is highly probable with the current sensor design. The implant longevity was independently verified by a third-party using sensor parameters to simulate sensor performance over time. Given the positive results of the study, the Company is now preparing for long-term animal studies, which are expected to begin later this year. On October 12, 2023, the Company issued a press release with respect to its initial Animal Study.

 

Effective as of October 6, 2023, Jolie Kahn resigned as Chief Financial Officer of GlucoTrack, Inc. (the “Company”) to pursue other career interests. Ms. Kahn’s resignation was not because of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices, including accounting principles and practices.

 

On October 11, 2023, the Company appointed James S Cardwell, 63, as Chief Financial Officer of the Company, effective immediately.

 

James Cardwell has over 16 years of experience as a Chief Financial Officer and Chief Operating Officer with a concentration in both SEC financial reporting and tax compliance. He has served as the Chief Operating Officer of the CFO Squad LLC, an accounting firm, since July 2015. In connection with his role at the CFO Squad LLC, he also served as interim Chief Financial Officer at several entities.

 

Mr. Cardwell has no family relationships with any of the Company’s directors or executive officers, and he is not a party to, and does not have any direct or indirect material interest in, any transaction requiring disclosure under Item 404(a) of Regulation S-K.

 

On October 11, 2023, in connection with Mr. Cardwell’s appointment as the Company’s Chief Financial Officer, Mr. Cardwell entered into a consulting agreement (the “Cardwell Consulting Agreement”) with the Company. Pursuant to the terms of the Cardwell Consulting Agreement, Mr. Cardwell will perform all duties typically required of a Chief Financial Officer. As compensation for his services, the Company shall pay Mr. Cardwell One Thousand Five Hundred Dollars ($1,500) per month. The Cardwell Consulting Agreement is for a term of one year. Either party may terminate the agreement upon thirty (30) day written notice.

 

The summary of our significant accounting policies is included under Item 7 – Management’s Discussion and Analysis of Financial Condition and Results of Operations of our fiscal 2022 Form 10-K. An accounting policy is deemed to be critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time the estimate is made, if different estimates reasonably could have been used, or if changes in the estimate that are reasonably possible could materially impact the financial statements. There have been no material changes to the critical accounting policies and estimates as filed in such report.

 

13

 

 

Liquidity and Capital Resources

 

To date, we have not generated any revenues and have experienced net losses and negative cash flows from our activities.

 

Since our incorporation, we have devoted substantially all our resources to research and product development and providing general and administrative support for these activities. Since our incorporation, we have incurred significant losses and negative cash flows from operations. During the nine months ended September 30, 2023, we incurred a net loss of approximately $4.7 million and used $4.1 million of cash in our operations. As of September 30, 2023, we had an accumulated deficit of approximately $107.4 million. We expect to continue to incur significant and increasing losses and do not expect positive cash flows from operations for the foreseeable future, and our net losses may fluctuate significantly from period to period depending on the timing of and expenditures on our research and development activities.

 

Results of Operations

 

The following discussion of our operating results explains material changes in our results of operations for the three- and nine-months ended September 30, 2023 compared with the same periods ended September 30, 2022. The discussion should be read in conjunction with the financial statements and related notes included elsewhere in this report.

 

Consolidated Results of Operations for the Three Months ended September 30, 2023 and 2022

 

Research and development expenses

 

Research and development expenses were approximately $1.7 million for the three-month period ended September 30, 2023, as compared to approximately $0.4 million for the prior-year period. The increase is attributable to staffing and professional fees for research and development expenses for two parallel projects, whereas, the prior-year period was funding only one project. Further to this, the implantable nature of the added project requires more development and manufacturing expenses than the initial hand-held product because of its additional regulatory requirements, including animal studies, which occurred during the period.

 

Research and development expenses consist primarily of salaries and other personnel-related expenses, materials, animal trials and other expenses. Salaries are higher than the prior-year as the Israeli operation was wound down in the third quarter of 2022 and we have since added similar staffing levels in the US, albeit at a higher functional level (senior management) because the Company was focused on building a strong US-based leadership team experienced in glucose sensing and diabetes technology. This team was established over the 2023 fiscal year, with two additions in third quarter (VP Marketing and Director Operations). This approach leveraged management of professional service organizations for hands-on engineering development activities, incurring professional service fees. We expect research and development expenses to increase in 2023 and beyond, primarily due to hiring additional personnel and developing and validating our implantable continuous glucose sensor, however, we may adjust or allocate the level of our research and development expenses based on available financial resources.

 

General and administrative expenses

 

General and administrative expenses were approximately $0.5 million for the three-month period ended September 30, 2023, as compared to approximately $0.49 million for the prior-year period. The increase is attributable to professional fees we accrued during the period.

 

General and administrative expenses consist primarily of professional services, salaries, consulting fees, insurance, travel expenses and other related expenses for executive, finance and administrative personnel, including stock-based compensation expenses. Other general and administrative costs and expenses include facility-related costs not otherwise included in research and development costs and expenses, and professional fees for legal and accounting services.

 

Financing income (expenses), net

 

Financing income, net was approximately $1 thousand for the three-month period ended September 30, 2023, as compared to financing income of approximately $2 thousand for the prior-year period. The change is immaterial.

 

Net Loss

 

Net loss was approximately $2.42 million for the three-month period ended September 30, 2023, as compared to approximately $0.9 million for the prior-year period. The increase in net loss is attributable primarily to the increase in our operating expenses, as described above.

 

14

 

 

Consolidated Results of Operations for the Nine Months ended September 30, 2023 and 2022

 

Research and development expenses

 

Research and development expenses were approximately $2.96 million for the nine-month period ended September 30, 2023, as compared to approximately $1.36 million for the prior-year period. The increase is attributable to the initiation of a project for a second product, the Implantable CGM, beginning in the fourth quarter of 2022. This project required ramp-up expenses to establish a functional chemistry lab with appropriate materials, equipment, and staff. This project also incurred additional professional fees for design, development, and production activities for animal studies we accrued during the period.

 

Research and development expenses consist primarily of salaries and other personnel-related expenses, materials, animal trials and other expenses. Salaries are higher than the prior-year as the Israeli operation was mostly engineering staff and was winding down in the second and third quarters of 2022; whereas the Company since built a strong US-based leadership team experienced in glucose sensing and diabetes technology. This team was established in 2023. This approach leveraged management of professional service organizations for hands-on engineering development activities, incurring professional service fees. We expect research and development expenses to increase in 2023 and beyond, primarily due to hiring additional personnel and developing and validating our implantable continuous glucose sensor, however, we may adjust or allocate the level of our research and development expenses based on available financial resources.

 

General and administrative expenses

 

General and administrative expenses were approximately $1.71 million for the nine-month period ended September 30, 2023, as compared to approximately $1.78 million for the prior-year period. The decrease is attributable to professional fees we accrued during the period.

 

General and administrative expenses consist primarily of professional services, salaries, consulting fees, insurance, travel expenses and other related expenses for executive, finance and administrative personnel, including stock-based compensation expenses. Other general and administrative costs and expenses include facility-related costs not otherwise included in research and development costs and expenses, and professional fees for legal and accounting services.

 

Financing income (expenses), net

 

Financing income, net was approximately $2 thousand for the nine-month period ended September 30, 2023, as compared to financing expense of approximately $2 thousand for the prior-year period. The change is immaterial.

 

Net Loss

 

Net loss was approximately $4.69 million for the nine-month period ended September 30, 2023, as compared to approximately $3.15 million for the prior-year period. The increase in net loss is attributable primarily to the increase in our operating expenses, as described above.

 

15

 

 

Cash Flows for the Nine Months Ended September 30, 2023 and 2022

 

Operating Activities

 

Net cash used in operating activities was approximately $4.14 million and approximately $2.79 million for the nine-month periods ended September 30, 2023 and 2022, respectively. Net cash used in operating activities primarily reflects the net loss for those periods of approximately $4.69 million and approximately $3.19 million, respectively.

 

Investing Activities

 

Net cash used in investing activities was $0 thousand and $4 thousand for the nine-month periods ended September 30, 2023 and 2022, respectively. Net cash used in investing activities primarily reflects the purchasing of fixed assets.

 

Financing Activities

 

Net cash provided by financing activities was approximately $8.73 million and $0 for the nine-month periods ended September 30, 2023 and 2022, respectively. Net cash provided by financing activities primarily reflects the net proceeds received from public offering, net of offering expenses.

 

Off-Balance Sheet Arrangements

 

As of September 30, 2023, we did not have any off-balance sheet arrangements as defined in Item 303(a)(4) of Regulation S-K.

 

Critical Accounting Policies

 

This Management’s Discussion and Analysis of Financial Condition and Results of Operations discuss our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). In connection with the preparation of our financial statements, we are required to make assumptions and estimates about future events and apply judgments that affect the reported amounts of assets, liabilities, expenses and the related disclosures. We base our assumptions, estimates and judgments on historical experience, current trends and other factors that management believes to be relevant at the time our condensed consolidated financial statements are prepared. On a regular basis, management reviews the accounting policies, assumptions, estimates and judgments to ensure that our financial statements are presented fairly and in accordance with U.S. GAAP. However, because future events and their effects cannot be determined with certainty, actual results could differ from our assumptions and estimates, and such differences could be material.

 

Going Concern Uncertainty

 

The development of the implantable continuous glucose sensor product is expected to require substantial further expenditures. We remain dependent upon external sources for financing our operations. Since inception, we have incurred substantial accumulated losses and negative operating cash flow and have a significant accumulated deficit. We do not have any committed external source of funds or other support for our development efforts, and we cannot be certain that additional funding will be available on acceptable terms, or at all. Until we can generate sufficient revenue to finance our cash requirements, which we may never do, we expect to finance our future cash needs through a combination of public or private equity offerings, debt financings, collaborations, government funding, strategic alliances, licensing arrangements, and other marketing or distribution arrangements, any of which may include terms that may adversely affect our stockholders’ rights. If we are unable to raise additional capital in sufficient amounts or on acceptable terms, we may have to significantly delay, scale back or discontinue our development or commercialization initiatives. Any of the above events could significantly harm our business, prospects, financial condition and results of operations and cause the price of our common stock to decline. However, in April 2023, we completed an underwriting U.S. public offering under which net proceeds of $8.73 million has been raised. As of September 30, 2023, we believe that our cash on hand will provide sufficient working capital to fund its current operations and animal trial program for the development of its Implantable CGM for a period of twelve-months subsequent to the reporting period.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

Not required for smaller reporting companies.

 

Item 4. Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures

 

Our management, with the participation of our Principal Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of September 30, 2023, or the Evaluation Date. Based on such evaluation, those officers have concluded that, as of the Evaluation Date, our disclosure controls and procedures are ineffective in recording, processing, summarizing and reporting, on a timely basis, information required to be included in periodic filings under the Exchange Act and that such information is not accumulated and communicated to management, including our principal executive and financial officers, in a manner sufficient to allow timely decisions regarding required disclosure, due to the material weaknesses in internal control over financial reporting related to lack of sufficient internal accounting personnel, segregation of duties, and lack of sufficient internal controls (including IT general controls) that encompass the Company as a whole with respect to entity and transactions level controls in order to ensure complete documentation of complex and non-routine transactions and adequate financial reporting.

 

Management has identified corrective actions to remediate such material weaknesses, which includes hiring additional employees and engaging in external financial reporting consultants. Management intends to implement procedures to remediate such material weaknesses during the fiscal year 2024; however, the implementation of these initiatives may not fully address any material weaknesses that we may have in our internal control over financial reporting. 

 

Changes in Internal Control over Financial Reporting

 

There were no changes in our internal control over financial reporting during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

16

 

 

PART II - OTHER INFORMATION

 

Item 1A. Risk Factors.

 

You should carefully consider the factors discussed in Part I, Item 1A., “Risk Factors” in our Annual Report for the fiscal year ended December 31, 2022, which could materially affect our business, financial position, or future results of operations. The risks described in our Annual Report for the fiscal year ended December 31, 2022, are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially adversely affect our business, financial position, or future results of operations. We may disclose changes to such factors or disclose additional factors from time to time in our future filings with the SEC. The risk factor set forth below supplements and updates the risk factors previously disclosed and should be read together with the risk factors described in our Annual Report for the fiscal year ended December 31, 2022 and with any risk factors we may include in subsequent periodic filings with the SEC.

 

We may fail to select or capitalize on the most scientifically, clinically or commercially promising or profitable product candidates.

 

Given the current momentum for continuous glucose monitoring (“CGM”) in the diabetes market, we have announced our decision to reset our priorities, improve our commercial outlook and refine our business strategy to focus on our implantable CGM technology. Should our efforts to focus on CGM not be successful, we will need to further evaluate our business strategy and, as a result, our Board of Directors may decide that it is in the best interest of our stockholders to dissolve our Company and liquidate our assets or otherwise modify our strategy in the future. In this regard, we may, from time to time, focus our product development efforts on different product candidates or may delay, suspend or terminate the future development of a product candidate at any time for strategic, business, financial or other reasons. As a result of changes in our strategy, we have and may in the future change or refocus our existing product development, commercialization and manufacturing activities. This could require changes in our facilities and our personnel. Any product development changes that we implement may not be successful. In particular, we may fail to select or capitalize on the most scientifically, clinically or commercially promising or profitable product candidates. Our decisions to allocate our research and development, management and financial resources toward particular product candidates may not lead to the development of viable commercial products and may divert resources from better opportunities. Similarly, our decisions to delay or terminate product development programs may also prove to be incorrect and could cause us to miss valuable opportunities.

 

Our failure to maintain compliance with Nasdaq’s continued listing requirements could result in the delisting of our Common Stock.

 

Our common stock is currently listed for trading on The Nasdaq Stock Market LLC. We must satisfy the continued listing requirements of Nasdaq, to maintain the listing of our common stock on The Nasdaq Stock Market LLC.

 

On May 26, 2023, we received notice from the Staff indicating that, based upon the closing bid price of our common stock for the prior 30 consecutive business days, we were not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on Nasdaq as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). We have 180 days from May 26, 2023, or through November 22, 2023, to regain compliance with the Bid Price Rule.

 

There can be no assurance that we will be able to regain and sustain compliance with all applicable requirements for continued listing on the Nasdaq Stock Market LLC. In the event that we are unable to regain and sustain compliance with all applicable requirements for continued listing on the Nasdaq, our common stock may be delisted from Nasdaq.

 

If our common stock were delisted from Nasdaq, trading of our common stock would most likely take place on an over-the-counter market established for unlisted securities, such as the OTCQB or the Pink Market maintained by OTC Markets Group Inc. An investor would likely find it less convenient to sell, or to obtain accurate quotations in seeking to buy, our common stock on an over-the-counter market, and many investors would likely not buy or sell our common stock due to difficulty in accessing over-the-counter markets, policies preventing them from trading in securities not listed on a national exchange or other reasons. In addition, as a delisted security, our common stock would be subject to SEC rules as a “penny stock,” which impose additional disclosure requirements on broker-dealers. The regulations relating to penny stocks, coupled with the typically higher cost per trade to the investor of penny stocks due to factors such as broker commissions generally representing a higher percentage of the price of a penny stock than of a higher-priced stock, would further limit the ability of investors to trade in our common stock. In addition, delisting would materially and adversely affect our ability to raise capital on terms acceptable to us, or at all, and may result in the potential loss of confidence by investors, suppliers, customers and employees and fewer business development opportunities. For these reasons and others, delisting would adversely affect the liquidity, trading volume and price of our common stock, causing the value of an investment in us to decrease and having an adverse effect on our business, financial condition and results of operations, including our ability to attract and retain qualified employees and to raise capital.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

None.

 

Item 3. Defaults Upon Senior Securities

 

None.

 

Item 4. Mine Safety Disclosures

 

None.

 

Item 5. Other Information

 

None.

 

Item 6. Exhibits.

 

Exhibit No.   Description
     
31.1   Certification of Principal Executive Officer and Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1   Certification of Principal Executive Officer and Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
10.1   Consulting Agreement dated October 11, 2023, by and between GlucoTrack, Inc. and James S. Cardwell (incorporated herein by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the SEC on October 12, 2023).
101.INS   Inline XBRL Instance Document
101.SCH   Inline XBRL Schema Document
101.CAL   Inline XBRL Calculation Linkbase Document
101.LAB   Inline XBRL Label Linkbase Document
101.PRE   Inline XBRL Presentation Linkbase Document
101.DEF   Inline XBRL Definition Linkbase Document
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

17

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Dated: November 14, 2023

 

  GLUCOTRACK, INC.
     
  By: /s/ James Cardwell
  Name: James Cardwell
  Title Chief Financial Officer
    (Principal Financial Officer)

 

18

 EX-31.1 2 ex31-1.htm

 

Exhibit 31.1

 

CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF

THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

 

I, Paul Goode, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q for the fiscal quarter ended September 30, 2023 of GlucoTrack, Inc.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  (a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  (b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  (c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  (d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 14, 2023 By: /s/ Paul Goode
    Paul Goode
    Principal Executive Officer

 

 

 EX-31 3 ex31-2.htm

 

Exhibit 31.2

 

CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF

THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

 

I, James Cardwell, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q for the fiscal quarter ended September 30, 2023 of GlucoTrack, Inc.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  (a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  (b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  (c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  (d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 14, 2023 By: /s/ James Cardwell
    James Cardwell
    Principal Financial Officer

 

 

 

 EX-32.1 4 ex32-1.htm

 

Exhibit 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report on Form 10-Q of GlucoTrack, Inc. (the “Company”) for the period ended September 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Paul Goode, Principal Executive Officer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

 

(1) the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
   
(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

  By: /s/ Paul Goode
    Paul Goode
    Principal Executive Officer
     
  Dated: November 14, 2023

 

 

 EX-32.2 5 ex32-2.htm

 

Exhibit 32.2

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report on Form 10-Q of GlucoTrack, Inc. (the “Company”) for the period ended September 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, James Cardwell, Principal Financial Officer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

 

(1) the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
   
(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

  By: /s/ James Cardwell
    James Cardwell
    Principal Financial Officer
     
  Dated: November 14, 2023

 

 

  

 EX-101.SCH 6 gctk-20230930.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - GENERAL link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - SIGNIFICANT TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - GENERAL (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - SCHEDULE OF ANTIDILUTIVE NET LOSS AND WEIGHTED AVERAGE (Details) link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - SIGNIFICANT TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 gctk-20230930_cal.xml INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 gctk-20230930_def.xml INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 gctk-20230930_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Receipts on Account of Shares [Member] AOCI Attributable to Parent [Member] Retained Earnings [Member] Prefunded Warrants [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Intellectual Property Purchase Agreement [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] Current assets Cash and cash equivalents Other current assets Total current assets Property and equipment, net Restricted cash TOTAL ASSETS LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities Accounts payable Other current liabilities Total current liabilities Non-current liabilities Loans from stockholders Total non-current liabilities Total liabilities Stockholders’ equity  Common Stock of $ 0.001 par value (“Common Stock”): 500,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 20,892,193 and 15,500,730 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively Additional paid-in capital Accumulated other comprehensive income Receipts on account of shares Accumulated deficit Total stockholders’ equity TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Research and development General and administrative Total operating expenses Operating loss Other expenses Finance expenses (income), net Net Loss Other comprehensive income: Foreign currency translation adjustment Comprehensive loss for the period Basic net loss per common stock Diluted net loss per common stock Weighted average number of common stock outstanding used in computing basic net loss per share Weighted average number of common stock outstanding used in computing diluted net loss per share Statement [Table] Statement [Line Items] Balance Balance, shares Loss for the period Other comprehensive income Deemed dividend resulted from trigger of down round protection feature of certain warrants granted Net proceeds received from underwritten U.S. public offering Net proceeds received from underwritten U.S. public offering, shares Issuance of restricted shares as compensation towards directors Issuance of restricted shares as compensation towards directors, shares Stock-based compensation Restricted shares to be issued as compensation towards directors Stock-based compensation Stock-based compensation, shares Balance Balance, shares Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Adjustments to reconcile net loss to net cash used in operating activities: Depreciation Stock-based compensation Issuance of restricted shares as compensation towards directors Linkage difference on principal of loans from stockholders Changes in assets and liabilities: Increase in other current assets Increase in accounts payable Increase (Decrease) in other current liabilities Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES: Purchase of property and equipment Net cash used in investing activities CASH FLOWS FROM FINANCING ACTIVITIES: Net proceeds received from underwritten U.S. public offering Net cash provided by financing activities Effect of exchange rate changes on cash and cash equivalents, and restricted cash Change in cash, cash equivalents, and restricted cash Cash, cash equivalents, and restricted cash at beginning of the period Cash, cash equivalents, and restricted cash, end of period Non-cash financing activities Deemed dividend upon trigger of down round protection Organization, Consolidation and Presentation of Financial Statements [Abstract] GENERAL Accounting Policies [Abstract] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Significant Transactions SIGNIFICANT TRANSACTIONS Subsequent Events [Abstract] SUBSEQUENT EVENTS Basis of Presentation SCHEDULE OF ANTIDILUTIVE NET LOSS AND WEIGHTED AVERAGE Accumulated deficit Net proceeds Net loss Deemed dividend related to trigger of down round protection feature (see Note 3A below) Net basic loss Net diluted loss Ordinary shares used in computing basic net loss per common stock Ordinary shares used in computing diluted net loss per common stock Shares of Common Stock to be issued upon achievement of performance milestone Description of common stock Gross proceeds Number of common shares issued Share price Exercise price Incremental and direct issuance costs Additional paid in capital Share based compensation Discount rate Minimum bid price Receipts on account of shares. Financing income expense net. Receipts on Account of Shares [Member] Adjustments to additional paid in capital deemed dividend resulted from trigger of down round protection feature of certain warrants granted. Stock to be issued during period value restricted stock award gross. Issuance of restricted shares as compensation to the board of directors. Linkage difference on principal of loans from stockholders . Proceeds received from underwritten public offering. Deemed dividend upon trigger of down round protection. Deemed dividend related to trigger of down round protection feature. Significant Transactions [Text Block] Prefunded warrants member. Intellectual Property Purchase Agreement [Member] Discount rate. Assets, Current Assets Liabilities, Current Liabilities, Noncurrent Liabilities Equity, Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) FinancingIncomeExpenseNet Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Comprehensive Income (Loss), Net of Tax, Attributable to Parent Shares, Outstanding Shares Issued, Value, Share-Based Payment Arrangement, before Forfeiture Share-Based Payment Arrangement, Noncash Expense IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors Increase (Decrease) in Other Current Assets Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities ProceedsReceivedFromUnderwrittenPublicOffering Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations EX-101.PRE 10 gctk-20230930_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover - shares
 9 Months Ended
Sep. 30, 2023
Nov. 14, 2023
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Sep. 30, 2023  
Document Fiscal Period Focus Q3  
Document Fiscal Year Focus 2023  
Current Fiscal Year End Date --12-31  
Entity File Number 001-41141  
Entity Registrant Name GLUCOTRACK, INC.  
Entity Central Index Key 0001506983  
Entity Tax Identification Number 98-0668934  
Entity Incorporation, State or Country Code DE  
Entity Address, Address Line One 301 Route 17 North  
Entity Address, Address Line Two Suite 800  
Entity Address, City or Town Rutherford  
Entity Address, State or Province NJ  
Entity Address, Postal Zip Code 07070  
City Area Code (201)  
Local Phone Number 842-7715  
Title of 12(b) Security Common Stock  
Trading Symbol GCTK  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   20,892,193
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets    
Cash and cash equivalents $ 6,888 $ 2,312
Other current assets 281 67
Total current assets 7,169 2,379
Property and equipment, net 17 40
Restricted cash 9 19
TOTAL ASSETS 7,195 2,438
Current liabilities    
Accounts payable 1,249 672
Other current liabilities 205 341
Total current liabilities 1,454 1,013
Non-current liabilities    
Loans from stockholders 184 195
Total non-current liabilities 184 195
Total liabilities 1,638 1,208
Stockholders’ equity    
 Common Stock of $ 0.001 par value (“Common Stock”): 500,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 20,892,193 and 15,500,730 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively 20 15
Additional paid-in capital 112,944 103,095
Accumulated other comprehensive income 34 17
Receipts on account of shares 4
Accumulated deficit (107,441) (101,901)
Total stockholders’ equity 5,557 1,230
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 7,195 $ 2,438
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Sep. 30, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 500,000,000 500,000,000
Common stock, shares issued 20,892,193 15,500,730
Common stock, shares outstanding 20,892,193 15,500,730
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]        
Research and development $ 1,693 $ 434 $ 2,962 $ 1,363
General and administrative 531 495 1,725 1,782
Total operating expenses 2,224 929 4,687 3,145
Operating loss 2,224 929 4,687 3,145
Other expenses 1 1
Finance expenses (income), net (1) (2) (2) 2
Net Loss 2,223 928 4,685 3,148
Other comprehensive income:        
Foreign currency translation adjustment (6) (1) (17) (36)
Comprehensive loss for the period $ 2,217 $ 929 $ 4,668 $ 3,112
Basic net loss per common stock $ (0.10) $ (0.06) $ (0.28) $ (0.20)
Diluted net loss per common stock $ (0.10) $ (0.06) $ (0.28) $ (0.20)
Weighted average number of common stock outstanding used in computing basic net loss per share 22,968,663 15,473,521 20,032,634 15,468,279
Weighted average number of common stock outstanding used in computing diluted net loss per share 22,968,663 15,473,521 20,032,634 15,468,279
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited) - USD ($)
$ in Thousands
Common Stock [Member]
Additional Paid-in Capital [Member]
Receipts on Account of Shares [Member]
AOCI Attributable to Parent [Member]
Retained Earnings [Member]
Total
Balance at Dec. 31, 2021 $ 15 $ 102,612 $ (6) $ (97,466) $ 5,155
Balance, shares at Dec. 31, 2021 15,452,285          
Loss for the period (3,148) (3,148)
Other comprehensive income 36 36
Issuance of restricted shares as compensation towards directors 20 20
Issuance of restricted shares as compensation towards directors, shares 11,275          
Restricted shares to be issued as compensation towards directors [1] 18 18
Stock-based compensation 274 274
Stock-based compensation, shares 13,105          
Balance at Sep. 30, 2022 $ 15 102,906 18 30 (100,614) 2,355
Balance, shares at Sep. 30, 2022 15,476,665          
Balance at Jun. 30, 2022 $ 15 102,821 9 31 (99,686) 3,190
Balance, shares at Jun. 30, 2022 15,473,262          
Loss for the period (928) (928)
Other comprehensive income (1) (1)
Issuance of restricted shares as compensation towards directors [1] 9 (9)
Issuance of restricted shares as compensation towards directors, shares 3,403          
Restricted shares to be issued as compensation towards directors 18 18
Stock-based compensation 76 76
Balance at Sep. 30, 2022 $ 15 102,906 18 30 (100,614) 2,355
Balance, shares at Sep. 30, 2022 15,476,665          
Balance at Dec. 31, 2022 $ 15 103,095 4 17 (101,901) 1,230
Balance, shares at Dec. 31, 2022 15,500,730          
Loss for the period (4,685) (4,685)
Other comprehensive income 17 17
Deemed dividend resulted from trigger of down round protection feature of certain warrants granted 855 (855)
Net proceeds received from underwritten U.S. public offering $ 5 8,725 8,730
Net proceeds received from underwritten U.S. public offering, shares 5,376,472          
Issuance of restricted shares as compensation towards directors [1] 9 (4) 5
Issuance of restricted shares as compensation towards directors, shares 14,991          
Stock-based compensation 260 260
Balance at Sep. 30, 2023 $ 20 112,944 34 (107,441) 5,557
Balance, shares at Sep. 30, 2023 20,892,193          
Balance at Jun. 30, 2023 $ 20 112,913 28 (105,218) 7,743
Balance, shares at Jun. 30, 2023 20,892,193          
Loss for the period (2,223) (2,223)
Other comprehensive income 6 6
Stock-based compensation 31 31
Balance at Sep. 30, 2023 $ 20 $ 112,944 $ 34 $ (107,441) $ 5,557
Balance, shares at Sep. 30, 2023 20,892,193          
[1] Represents amount lower than $1.
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES    
Loss for the period $ (4,685) $ (3,148)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 21 19
Stock-based compensation 260 274
Issuance of restricted shares as compensation towards directors 5 38
Linkage difference on principal of loans from stockholders 4 8
Changes in assets and liabilities:    
Increase in other current assets (216) (148)
Increase in accounts payable 598 117
Increase (Decrease) in other current liabilities (134) 51
Net cash used in operating activities (4,147) (2,789)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchase of property and equipment (4)
Net cash used in investing activities (4)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Net proceeds received from underwritten U.S. public offering 8,730
Net cash provided by financing activities 8,730
Effect of exchange rate changes on cash and cash equivalents, and restricted cash (17) (40)
Change in cash, cash equivalents, and restricted cash 4,566 (2,833)
Cash, cash equivalents, and restricted cash at beginning of the period 2,331 6,113
Cash, cash equivalents, and restricted cash, end of period 6,897 3,280
Non-cash financing activities    
Deemed dividend upon trigger of down round protection $ 855
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.3
GENERAL
 9 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
GENERAL

NOTE 1 – GENERAL

 

A. GlucoTrack Inc. (the “Company”) was incorporated on May 18, 2010 under the laws of the State of Delaware. The Company is a medical device company, focused on the design, development and commercialization of novel technologies for use by people with diabetes. The Company is currently developing an Implantable Continuous Glucose Monitor (CGM) for persons with Type 1 diabetes and insulin-dependent Type 2 diabetes.
   
B. Liquidity and capital resources
   
  To date, the Company has not yet generated significant revenues from GlucoTrack product, a non-invasive spot measurement glucose sensor that has been discontinued. In addition, development and commercialization of the Implantable CGM is expected to require substantial expenditures; therefore, the Company is dependent upon external sources for financing its operations. As of September 30, 2023, the Company has incurred accumulated deficit of $107,441 thousand. Furthermore, the Company has generated operating losses and negative operating cash flow for all reported periods.
   
  Management has considered the significance of such conditions in relation to the Company’s ability to meet its current obligations and to achieve its business targets and determined that these conditions do not raise substantial doubt about the Company’s ability to continue as a going concern, taking into consideration the net proceeds received in total amount of $8,730 thousand upon closing of a public offering through prospectus supplement on Form S-3 on April 17, 2023 (see also Note 3A below). As of September 30, 2023, our cash on hand will provide sufficient working capital to fund its current operations and animal trial program for the development of its Implantable CGM for a period of twelve-months subsequent to the reporting period.

 
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.23.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

A. Basis of Presentation

 

  1. Accounting Principles
     
    The accompanying unaudited condensed consolidated interim financial statements and related notes should be read in conjunction with the consolidated financial statements and related notes contained in the Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the Securities and Exchange Commission (“SEC”) on March 31, 2023. The unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC related to interim financial statements. As permitted under those rules, certain information and footnote disclosures normally required or included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The financial information contained herein is unaudited; however, management believes all adjustments have been made that are considered necessary to present fairly the results of the Company’s financial position and operating results for the interim periods. All such adjustments are of a normal recurring nature.
     
    The results for the period of nine months ended September 30, 2023 are not necessarily indicative of the results to be expected for the year ending December 31, 2023 or for any other interim period or for any future period.
     
  2. Principles of Consolidation
     
    The consolidated financial statements include the accounts of the Company and its subsidiary. Significant intercompany balances and transactions have been eliminated in consolidation.

 

 

GLUCOTRACK INC.

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)

 

A. Basis of Presentation

 

  3. Net Loss Per Common Stock
     
    Basic net loss per Common Stock is computed by dividing the loss for the period applicable for holders of Common Stock and pre-funded warrants (after considering the effect of deemed dividend related to trigger of down round protection feature) dividend by the weighted average number of outstanding shares of Common Stock and shares of Common Stock to be issued upon exercise of pre-funded warrants (see Note 3A below) or shares of Common Stock to be issued upon achievement of performance milestone (see Note 3B below) during the period. Diluted loss per share gives effect to all potentially dilutive common shares outstanding during the period using the treasury stock method with respect to stock options and certain stock warrants. In computing diluted loss per share, the average stock price for the period is used in determining the number of Common Stock assumed to be purchased from the exercise of stock options or stock warrants.
     
    Shares to be issued upon exercise of all stock options and stock warrants have been excluded from the calculation of the diluted net loss per Common Stock for all the reported periods for which net loss was reported because the effect of the Common Stock issuable upon exercise of these instruments was anti-dilutive.
     
    The net loss and the weighted average number of shares of Common Stock used in computing basic and diluted net loss per share for the period of three and nine months ended September 30, 2023 and 2022, is as follows:

 

   2023   2022   2023   2022 
     US dollars in thousands
(except share data)		    

US dollars in thousands

(except share data)

 
    

Three-month period

ended
September 30,

    

Nine-month period

ended
September 30,

 
     (Unaudited)     (Unaudited) 
     2023       2022     2023   2022 
                         
Numerator:                          
Net loss  $ 2,223     $ 928     $4,685   $3,148 
Deemed dividend related to trigger of down round protection feature (see Note 3A below)    -       -      855    - 
Net loss attributable to common stockholders  $ 2,223     $ 928     $5,540   $3,148 
                           
Denominator:                          
Shares of Common Stock used in computing basic and diluted net loss per common stock    20,892,193       15,473,521      18,792,950    15,468,279 
Shares of Common Stock to be issued upon exercise of pre-funded warrants    -       1,976,470      1,206,228    - 
Shares of Common Stock to be issued upon achievement of performance milestone            100,000      33,456      
Basic and diluted net loss per common stock  $ (0.10 )   $ (0.06 )   $(0.28)  $(0.2)

 

 

GLUCOTRACK INC.

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONT.)

 
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.23.3
SIGNIFICANT TRANSACTIONS
 9 Months Ended
Sep. 30, 2023
Significant Transactions  
SIGNIFICANT TRANSACTIONS

NOTE 3 - SIGNIFICANT TRANSACTIONS

 

A. Completion of underwritten U.S. public offering
   
  On April 13, 2023, the Company completed an underwritten public offering under which the Company received gross proceeds of approximately $10 million for issuance of (i) 5,376,472 shares of common stock and (ii) 1,976,470 pre-funded warrants at a price to the public of $1.36 per share. The pre-funded warrants are exercisable for the same number of shares of common stock and may be exercised at any time until exercised in full at an exercise price of $0.001.
   
  Upon satisfaction of customary closing conditions, the closing date of the above underwritten public offering was April 17, 2023 (the “Closing Date”).
   
  The Company received substantially all the pre-funded warrant’s proceeds upfront (without any conditions) as part of the pre-funded warrant’s purchase price and in return the Company is obligated to issue fixed number of shares of common stock to the holders. Thus, pre-funded warrants were accounted for and were classified as additional paid-in capital as part of the Company’s stockholders’ equity.
   
  Total incremental and direct issuance costs amounted to $1,270 thousand. These expenses were deducted from additional paid-in capital as they were allocated to shares of Common Stock and pre-funded warrants.

 

  Upon closing of underwritten U.S. public offering, a down round protection feature of certain warrants granted in previous years to service providers was triggered by the way of reduction of their exercise price from a price in a range of $3.35-$70.20 to a price of $1.36 which represented the above public offering price. Such reduction was accounted for as deemed dividend estimated at total amount of $855 thousand which was recorded as part of the additional paid-in capital versus increase of accumulated deficit. Regarding the effect of the loss per share, see also Note 2.A.3. above.

 

B. Intellectual Property Purchase Agreement 
   
  In the middle of June 2023, the Company achieved the first performance milestone out of the five performance milestones outlined in the Intellectual Property Purchase Agreement (the “Agreement”) executed between the Company and Paul Goode, which is the Company’s Chief Executive Officer (the “Seller”) as October 7, 2022 (the “Closing Date”). As a result, upon the date of fulfillment of the performance milestone the Company is committed to issue 100,000 restricted shares to the Seller. During the periods of three and nine months ended September 30, 2023, the Company recorded stock-based compensation expenses of $0 and $131 thousand, respectively, which represents the quoted price of its Common Stock at the Closing Date, after taking into consideration a discount for lack of marketability at a rate of 30.4% over a restriction period of 1-year. As of September 30, 2023, achievement of all other performance milestones was not considered probable and thus no stock-based compensation expenses were recorded with respect to thereof.
   
C. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
   
  On May 26, 2023, the Company received a letter from Nasdaq that it no longer complies with Rule 5550(a)(2) of Nasdaq’s Listing Rules (the “Rules”) which require listed securities to maintain a minimum bid price of $1 per share. However, the Rules provide the Company a compliance period of 180-days to regain compliance under which if at any time during 180-days period the closing bid price of the Company’s security is at least $1 for a minimum of ten consecutive business days, Nasdaq will provide the Company written confirmation of compliance and this matter will be closed. In the event the Company does not regain compliance by the 180th day, the Company may be eligible for additional time to regain compliance or may face delisting.

 
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.23.3
SUBSEQUENT EVENTS
 9 Months Ended
Sep. 30, 2023
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

NOTE 4 - SUBSEQUENT EVENTS

 

The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the condensed interim consolidated financial statements were issued November 14, 2023. Based upon this review, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements.
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.23.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Basis of Presentation

A. Basis of Presentation

 

  1. Accounting Principles
     
    The accompanying unaudited condensed consolidated interim financial statements and related notes should be read in conjunction with the consolidated financial statements and related notes contained in the Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the Securities and Exchange Commission (“SEC”) on March 31, 2023. The unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC related to interim financial statements. As permitted under those rules, certain information and footnote disclosures normally required or included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The financial information contained herein is unaudited; however, management believes all adjustments have been made that are considered necessary to present fairly the results of the Company’s financial position and operating results for the interim periods. All such adjustments are of a normal recurring nature.
     
    The results for the period of nine months ended September 30, 2023 are not necessarily indicative of the results to be expected for the year ending December 31, 2023 or for any other interim period or for any future period.
     
  2. Principles of Consolidation
     
    The consolidated financial statements include the accounts of the Company and its subsidiary. Significant intercompany balances and transactions have been eliminated in consolidation.

 

 

GLUCOTRACK INC.

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)

 

A. Basis of Presentation

 

  3. Net Loss Per Common Stock
     
    Basic net loss per Common Stock is computed by dividing the loss for the period applicable for holders of Common Stock and pre-funded warrants (after considering the effect of deemed dividend related to trigger of down round protection feature) dividend by the weighted average number of outstanding shares of Common Stock and shares of Common Stock to be issued upon exercise of pre-funded warrants (see Note 3A below) or shares of Common Stock to be issued upon achievement of performance milestone (see Note 3B below) during the period. Diluted loss per share gives effect to all potentially dilutive common shares outstanding during the period using the treasury stock method with respect to stock options and certain stock warrants. In computing diluted loss per share, the average stock price for the period is used in determining the number of Common Stock assumed to be purchased from the exercise of stock options or stock warrants.
     
    Shares to be issued upon exercise of all stock options and stock warrants have been excluded from the calculation of the diluted net loss per Common Stock for all the reported periods for which net loss was reported because the effect of the Common Stock issuable upon exercise of these instruments was anti-dilutive.
     
    The net loss and the weighted average number of shares of Common Stock used in computing basic and diluted net loss per share for the period of three and nine months ended September 30, 2023 and 2022, is as follows:

 

   2023   2022   2023   2022 
     US dollars in thousands
(except share data)		    

US dollars in thousands

(except share data)

 
    

Three-month period

ended
September 30,

    

Nine-month period

ended
September 30,

 
     (Unaudited)     (Unaudited) 
     2023       2022     2023   2022 
                         
Numerator:                          
Net loss  $ 2,223     $ 928     $4,685   $3,148 
Deemed dividend related to trigger of down round protection feature (see Note 3A below)    -       -      855    - 
Net loss attributable to common stockholders  $ 2,223     $ 928     $5,540   $3,148 
                           
Denominator:                          
Shares of Common Stock used in computing basic and diluted net loss per common stock    20,892,193       15,473,521      18,792,950    15,468,279 
Shares of Common Stock to be issued upon exercise of pre-funded warrants    -       1,976,470      1,206,228    - 
Shares of Common Stock to be issued upon achievement of performance milestone            100,000      33,456      
Basic and diluted net loss per common stock  $ (0.10 )   $ (0.06 )   $(0.28)  $(0.2)

 
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.23.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
 9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
SCHEDULE OF ANTIDILUTIVE NET LOSS AND WEIGHTED AVERAGE

   2023   2022   2023   2022 
     US dollars in thousands
(except share data)		    

US dollars in thousands

(except share data)

 
    

Three-month period

ended
September 30,

    

Nine-month period

ended
September 30,

 
     (Unaudited)     (Unaudited) 
     2023       2022     2023   2022 
                         
Numerator:                          
Net loss  $ 2,223     $ 928     $4,685   $3,148 
Deemed dividend related to trigger of down round protection feature (see Note 3A below)    -       -      855    - 
Net loss attributable to common stockholders  $ 2,223     $ 928     $5,540   $3,148 
                           
Denominator:                          
Shares of Common Stock used in computing basic and diluted net loss per common stock    20,892,193       15,473,521      18,792,950    15,468,279 
Shares of Common Stock to be issued upon exercise of pre-funded warrants    -       1,976,470      1,206,228    - 
Shares of Common Stock to be issued upon achievement of performance milestone            100,000      33,456      
Basic and diluted net loss per common stock  $ (0.10 )   $ (0.06 )   $(0.28)  $(0.2)
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.23.3
GENERAL (Details Narrative) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Accumulated deficit $ 107,441 $ 101,901
Net proceeds $ 8,730  
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.23.3
SCHEDULE OF ANTIDILUTIVE NET LOSS AND WEIGHTED AVERAGE (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Net loss $ 2,223 $ 928 $ 4,685 $ 3,148
Deemed dividend related to trigger of down round protection feature (see Note 3A below) 855
Net basic loss 2,223 928 5,540 3,148
Net diluted loss $ 2,223 $ 928 $ 5,540 $ 3,148
Ordinary shares used in computing basic net loss per common stock 22,968,663 15,473,521 20,032,634 15,468,279
Ordinary shares used in computing diluted net loss per common stock 22,968,663 15,473,521 20,032,634 15,468,279
Shares of Common Stock to be issued upon achievement of performance milestone   100,000 33,456  
Basic net loss per common stock $ (0.10) $ (0.06) $ (0.28) $ (0.20)
Diluted net loss per common stock $ (0.10) $ (0.06) $ (0.28) $ (0.20)
Prefunded Warrants [Member]        
Ordinary shares used in computing basic net loss per common stock 20,892,193 15,473,521 18,792,950 15,468,279
Ordinary shares used in computing diluted net loss per common stock 20,892,193 15,473,521 18,792,950 15,468,279
Shares of Common Stock to be issued upon achievement of performance milestone 1,976,470 1,206,228
Basic net loss per common stock $ (0.10) $ (0.06) $ (0.28) $ (0.2)
Diluted net loss per common stock $ (0.10) $ (0.06) $ (0.28) $ (0.2)
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.23.3
SIGNIFICANT TRANSACTIONS (Details Narrative) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 9 Months Ended
Apr. 13, 2023
Sep. 30, 2023
Sep. 30, 2023
May 26, 2023
Description of common stock the Company received gross proceeds of approximately $10 million for issuance of (i) 5,376,472 shares of common stock and (ii) 1,976,470 pre-funded warrants at a price to the public of $1.36 per share. The pre-funded warrants are exercisable for the same number of shares of common stock and may be exercised at any time until exercised in full at an exercise price of $0.001.      
Gross proceeds $ 10,000      
Exercise price $ 1.36      
Incremental and direct issuance costs $ 1,270      
Additional paid in capital $ 855      
Minimum bid price       $ 1
Intellectual Property Purchase Agreement [Member]        
Number of common shares issued     100,000  
Share based compensation   $ 0 $ 131  
Discount rate   30.40% 30.40%  
Minimum [Member]        
Exercise price $ 3.35      
Maximum [Member]        
Exercise price $ 70.20      
Common Stock [Member]        
Number of common shares issued 5,376,472   5,376,472  
Prefunded Warrants [Member]        
Number of common shares issued 1,976,470      
Share price $ 1.36      
Exercise price $ 0.001      
XML 26 form10-q_htm.xml IDEA: XBRL DOCUMENT 0001506983 2023-01-01 2023-09-30 0001506983 2023-11-14 0001506983 2023-09-30 0001506983 2022-12-31 0001506983 2023-07-01 2023-09-30 0001506983 2022-07-01 2022-09-30 0001506983 2022-01-01 2022-09-30 0001506983 us-gaap:CommonStockMember 2022-12-31 0001506983 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001506983 GCTK:ReceiptsOnAccountOfSharesMember 2022-12-31 0001506983 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001506983 us-gaap:RetainedEarningsMember 2022-12-31 0001506983 us-gaap:CommonStockMember 2023-06-30 0001506983 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001506983 GCTK:ReceiptsOnAccountOfSharesMember 2023-06-30 0001506983 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001506983 us-gaap:RetainedEarningsMember 2023-06-30 0001506983 2023-06-30 0001506983 us-gaap:CommonStockMember 2021-12-31 0001506983 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001506983 GCTK:ReceiptsOnAccountOfSharesMember 2021-12-31 0001506983 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001506983 us-gaap:RetainedEarningsMember 2021-12-31 0001506983 2021-12-31 0001506983 us-gaap:CommonStockMember 2022-06-30 0001506983 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001506983 GCTK:ReceiptsOnAccountOfSharesMember 2022-06-30 0001506983 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001506983 us-gaap:RetainedEarningsMember 2022-06-30 0001506983 2022-06-30 0001506983 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001506983 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-09-30 0001506983 GCTK:ReceiptsOnAccountOfSharesMember 2023-01-01 2023-09-30 0001506983 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-09-30 0001506983 us-gaap:RetainedEarningsMember 2023-01-01 2023-09-30 0001506983 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001506983 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001506983 GCTK:ReceiptsOnAccountOfSharesMember 2023-07-01 2023-09-30 0001506983 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001506983 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001506983 us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001506983 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-09-30 0001506983 GCTK:ReceiptsOnAccountOfSharesMember 2022-01-01 2022-09-30 0001506983 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-09-30 0001506983 us-gaap:RetainedEarningsMember 2022-01-01 2022-09-30 0001506983 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001506983 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001506983 GCTK:ReceiptsOnAccountOfSharesMember 2022-07-01 2022-09-30 0001506983 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0001506983 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001506983 us-gaap:CommonStockMember 2023-09-30 0001506983 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001506983 GCTK:ReceiptsOnAccountOfSharesMember 2023-09-30 0001506983 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001506983 us-gaap:RetainedEarningsMember 2023-09-30 0001506983 us-gaap:CommonStockMember 2022-09-30 0001506983 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001506983 GCTK:ReceiptsOnAccountOfSharesMember 2022-09-30 0001506983 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0001506983 us-gaap:RetainedEarningsMember 2022-09-30 0001506983 2022-09-30 0001506983 GCTK:PrefundedWarrantsMember 2023-07-01 2023-09-30 0001506983 GCTK:PrefundedWarrantsMember 2022-07-01 2022-09-30 0001506983 GCTK:PrefundedWarrantsMember 2023-01-01 2023-09-30 0001506983 GCTK:PrefundedWarrantsMember 2022-01-01 2022-09-30 0001506983 2023-04-13 2023-04-13 0001506983 us-gaap:CommonStockMember 2023-04-13 2023-04-13 0001506983 GCTK:PrefundedWarrantsMember 2023-04-13 2023-04-13 0001506983 GCTK:PrefundedWarrantsMember 2023-04-13 0001506983 srt:MinimumMember 2023-04-13 0001506983 srt:MaximumMember 2023-04-13 0001506983 2023-04-13 0001506983 GCTK:IntellectualPropertyPurchaseAgreementMember 2023-01-01 2023-09-30 0001506983 GCTK:IntellectualPropertyPurchaseAgreementMember 2023-07-01 2023-09-30 0001506983 2023-05-26 iso4217:USD shares iso4217:USD shares pure false Q3 --12-31 0001506983 10-Q true 2023-09-30 2023 false 001-41141 GLUCOTRACK, INC. DE 98-0668934 301 Route 17 North Suite 800 Rutherford NJ 07070 (201) 842-7715 Common Stock GCTK NASDAQ Yes Yes Non-accelerated Filer true false false 20892193 6888000 2312000 281000 67000 7169000 2379000 17000 40000 9000 19000 7195000 2438000 1249000 672000 205000 341000 1454000 1013000 184000 195000 184000 195000 1638000 1208000 0.001 0.001 500000000 500000000 20892193 20892193 15500730 15500730 20000 15000 0.001 0.001 500000000 500000000 20892193 20892193 15500730 15500730 20000 15000 112944000 103095000 34000 17000 4000 -107441000 -101901000 5557000 1230000 7195000 2438000 1693000 434000 2962000 1363000 531000 495000 1725000 1782000 2224000 929000 4687000 3145000 -2224000 -929000 -4687000 -3145000 1000 1000 1000 2000 2000 -2000 -2223000 -928000 -4685000 -3148000 6000 1000 17000 36000 -2217000 -929000 -4668000 -3112000 -0.10 -0.10 -0.06 -0.06 -0.28 -0.28 -0.20 -0.20 22968663 22968663 15473521 15473521 20032634 20032634 15468279 15468279 15500730 15000 103095000 4000 17000 -101901000 1230000 -4685000 -4685000 17000 17000 855000 -855000 5376472 5000 8725000 8730000 14991 9000 -4000 5000 260000 260000 20892193 20000 112944000 34000 -107441000 5557000 20892193 20000 112913000 28000 -105218000 7743000 -2223000 -2223000 6000 6000 31000 31000 20892193 20000 112944000 34000 -107441000 5557000 15452285 15000 102612000 -6000 -97466000 5155000 -3148000 -3148000 36000 36000 11275 20000 20000 18000 18000 13105 274000 274000 15476665 15000 102906000 18000 30000 -100614000 2355000 15473262 15000 102821000 9000 31000 -99686000 3190000 15473262 15000 102821000 9000 31000 -99686000 3190000 -928000 -928000 -1000 -1000 3403 9000 -9000 18000 18000 76000 76000 15476665 15000 102906000 18000 30000 -100614000 2355000 15476665 15000 102906000 18000 30000 -100614000 2355000 -4685000 -3148000 21000 19000 260000 274000 5000 38000 4000 8000 216000 148000 598000 117000 -134000 51000 -4147000 -2789000 4000 -4000 8730000 8730000 -17000 -40000 4566000 -2833000 2331000 6113000 6897000 3280000 855000 <p id="xdx_80B_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zXHSe5s0l2D4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 – <span id="xdx_829_z1DRyu4H075d">GENERAL</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GlucoTrack Inc. (the “Company”) was incorporated on May 18, 2010 under the laws of the State of Delaware. The Company is a medical device company, focused on the design, development and commercialization of novel technologies for use by people with diabetes. The Company is currently developing an Implantable Continuous Glucose Monitor (CGM) for persons with Type 1 diabetes and insulin-dependent Type 2 diabetes.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity and capital resources</b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To date, the Company has not yet generated significant revenues from GlucoTrack product, a non-invasive spot measurement glucose sensor that has been discontinued. In addition, development and commercialization of the Implantable CGM is expected to require substantial expenditures; therefore, the Company is dependent upon external sources for financing its operations. As of September 30, 2023, the Company has incurred accumulated deficit of $<span id="xdx_900_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn3n3_di_c20230930_zsdmboe86ou6" title="Accumulated deficit">107,441</span> thousand. Furthermore, the Company has generated operating losses and negative operating cash flow for all reported periods.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management has considered the significance of such conditions in relation to the Company’s ability to meet its current obligations and to achieve its business targets and determined that these conditions do not raise substantial doubt about the Company’s ability to continue as a going concern, taking into consideration the net proceeds received in total amount of $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pn3n3_c20230101__20230930_znQxvr7Dkv8d" title="Net proceeds">8,730</span> thousand upon closing of a public offering through prospectus supplement on Form S-3 on April 17, 2023 (see also Note 3A below). As of September 30, 2023, our cash on hand will provide sufficient working capital to fund its current operations and animal trial program for the development of its Implantable CGM for a period of twelve-months subsequent to the reporting period.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> -107441000 8730000 <p id="xdx_80B_eus-gaap--SignificantAccountingPoliciesTextBlock_zjibmlbbMTUb" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 68.05pt; text-align: justify; text-indent: -68.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 – <span id="xdx_826_z4dGoMs5dKFd">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zAvaugVlqKXh" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A. <span id="xdx_86D_z0nQGjyfhBDi">Basis of Presentation</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accounting Principles</b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited condensed consolidated interim financial statements and related notes should be read in conjunction with the consolidated financial statements and related notes contained in the Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the Securities and Exchange Commission (“SEC”) on March 31, 2023. The unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC related to interim financial statements. As permitted under those rules, certain information and footnote disclosures normally required or included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The financial information contained herein is unaudited; however, management believes all adjustments have been made that are considered necessary to present fairly the results of the Company’s financial position and operating results for the interim periods. All such adjustments are of a normal recurring nature.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The results for the period of nine months ended September 30, 2023 are not necessarily indicative of the results to be expected for the year ending December 31, 2023 or for any other interim period or for any future period.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principles of Consolidation</b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements include the accounts of the Company and its subsidiary. Significant intercompany balances and transactions have been eliminated in consolidation.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 68.05pt; text-align: justify; text-indent: -68.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A. Basis of Presentation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net Loss Per Common Stock</b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic net loss per Common Stock is computed by dividing the loss for the period applicable for holders of Common Stock and pre-funded warrants (after considering the effect of deemed dividend related to trigger of down round protection feature) dividend by the weighted average number of outstanding shares of Common Stock and shares of Common Stock to be issued upon exercise of pre-funded warrants (see Note 3A below) or shares of Common Stock to be issued upon achievement of performance milestone (see Note 3B below) during the period. Diluted loss per share gives effect to all potentially dilutive common shares outstanding during the period using the treasury stock method with respect to stock options and certain stock warrants. In computing diluted loss per share, the average stock price for the period is used in determining the number of Common Stock assumed to be purchased from the exercise of stock options or stock warrants. </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares to be issued upon exercise of all stock options and stock warrants have been excluded from the calculation of the diluted net loss per Common Stock for all the reported periods for which net loss was reported because the effect of the Common Stock issuable upon exercise of these instruments was anti-dilutive.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The net loss and the weighted average number of shares of Common Stock used in computing basic and diluted net loss per share for the period of three and nine months ended September 30, 2023 and 2022, is as follows:</span></td></tr> </table> <p style="margin-top: 0; margin-bottom: 0"> </p> <p id="xdx_899_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z1jnpyhC5CL4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_z0GrGgSm5VS" style="display: none">SCHEDULE OF ANTIDILUTIVE NET LOSS AND WEIGHTED AVERAGE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_490_20230701__20230930_zFZrrMi15bRc" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49B_20220701__20220930_zJq14X6nIAKl" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49E_20230101__20230930_zMRDdgqjZ7F1" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_493_20220101__20220930_z7sn6N8uOJt7" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><b> </b></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td colspan="5" style="border-bottom: Black 1.5pt solid; text-align: center"><b>US dollars in thousands<br/> (except share data)</b></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="text-align: center; margin-top: 0; margin-bottom: 0"><b>US dollars in thousands</b></p> <p style="text-align: center; margin-top: 0; margin-bottom: 0"><b>(except share data)</b></p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><b> </b></td> </tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><b> </b></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td colspan="5" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><b>Three-month period</b></p> <p style="margin-top: 0; margin-bottom: 0"><b>ended<br/> September 30,</b></p></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><b>Nine-month period</b></p> <p style="margin-top: 0; margin-bottom: 0"><b>ended<br/> September 30,</b></p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><b> </b></td> </tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><b> </b></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td colspan="5" style="border-bottom: Black 1.5pt solid; text-align: center"><b>(Unaudited)</b></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>(Unaudited)</b></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><b> </b></td> </tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><b> </b></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><b>2023</b></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><b>2022</b></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>2023</b></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><b> </b></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>2022</b></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><b> </b></td> </tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Numerator:</td><td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td> </tr> <tr id="xdx_40C_eus-gaap--NetIncomeLoss_iN_pn3n3_di_znrls8icMfT1" style="vertical-align: bottom; background-color: White"> <td style="width: 48%; text-align: left; padding-left: 10pt">Net loss</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">2,223</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">928</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,685</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,148</td><td style="width: 1%; text-align: left"> </td> </tr> <tr id="xdx_404_ecustom--DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature_pn3n3_zEKOYy4nwhC3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Deemed dividend related to trigger of down round protection feature (see Note 3A below)</td><td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0551">-</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0552">-</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">855</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0554">-</span></td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Net loss attributable to common stockholders</td><td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_90A_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_c20230701__20230930_zFTDUcj3yxZd" title="Net basic loss"><span id="xdx_903_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_c20230701__20230930_zZEkcmnxutf7" title="Net diluted loss">2,223</span></span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_901_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_c20220701__20220930_z5UNj3cLyWx1"><span id="xdx_90D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_c20220701__20220930_zgyXH0LFwnqe" title="Net diluted loss">928</span></span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_900_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_c20230101__20230930_zMh1gCmNbY76" title="Net basic loss"><span id="xdx_908_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_c20230101__20230930_zenTt4oUhBIg" title="Net diluted loss">5,540</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_c20220101__20220930_zWQo4Z7Oldbk" title="Net basic loss"><span id="xdx_906_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_c20220101__20220930_zQJJuRVC8NQ6" title="Net diluted loss">3,148</span></span></td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>Denominator:</td><td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Shares of Common Stock used in computing basic and diluted net loss per common stock</td><td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zvvUzbcknn" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zPCuDduXoOCe" title="Ordinary shares used in computing diluted net loss per common stock">20,892,193</span></span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zu5sEUUxAoeb" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zwDav1GfMM5f" title="Ordinary shares used in computing diluted net loss per common stock">15,473,521</span></span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zwXTpj81EBrk" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zo9ybq7bnnLi" title="Ordinary shares used in computing diluted net loss per common stock">18,792,950</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_z5u3xnxjAQS5" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zz2o8X5wmD7h" title="Ordinary shares used in computing diluted net loss per common stock">15,468,279</span></span></td><td style="text-align: left"> </td> </tr> <tr id="xdx_406_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_hus-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_znBMdvwMlOf8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Shares of Common Stock to be issued upon exercise of pre-funded warrants</td><td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0587">-</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,976,470</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,206,228</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0590">-</span></span></td><td style="text-align: left"> </td> </tr> <tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_z3wA5P3Zxj1l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Shares of Common Stock to be issued upon achievement of performance milestone</td><td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">100,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">33,456</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Basic and diluted net loss per common stock</td><td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_907_eus-gaap--EarningsPerShareBasic_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zL8Pf8rxO0J4" title="Basic net loss per common stock"><span id="xdx_907_eus-gaap--EarningsPerShareDiluted_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zytmV3sQdon3" title="Diluted net loss per common stock">(0.10</span></span></td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_902_eus-gaap--EarningsPerShareBasic_pid_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zcHS4b94fcP5" title="Basic net loss per common stock"><span id="xdx_902_eus-gaap--EarningsPerShareDiluted_pid_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zxUFdjZegsj4" title="Diluted net loss per common stock">(0.06</span></span></td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--EarningsPerShareBasic_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zKrVxnCydPYe" title="Basic net loss per common stock"><span id="xdx_903_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zn3MugNpctX9" title="Diluted net loss per common stock">(0.28</span></span></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_903_eus-gaap--EarningsPerShareBasic_pid_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zMFyAM4JX2A6" title="Basic net loss per common stock"><span id="xdx_903_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zkWA8MI1Kce7" title="Diluted net loss per common stock">(0.2</span></span></td><td style="text-align: left">)</td> </tr> </table> <p id="xdx_8AB_z2BsDtBMB8Ph" style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_857_zKWXzzExHYI8" style="font: 10pt Times New Roman, Times, Serif; display: none; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONT.) </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zAvaugVlqKXh" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A. <span id="xdx_86D_z0nQGjyfhBDi">Basis of Presentation</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 46.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accounting Principles</b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited condensed consolidated interim financial statements and related notes should be read in conjunction with the consolidated financial statements and related notes contained in the Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the Securities and Exchange Commission (“SEC”) on March 31, 2023. The unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC related to interim financial statements. As permitted under those rules, certain information and footnote disclosures normally required or included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The financial information contained herein is unaudited; however, management believes all adjustments have been made that are considered necessary to present fairly the results of the Company’s financial position and operating results for the interim periods. All such adjustments are of a normal recurring nature.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The results for the period of nine months ended September 30, 2023 are not necessarily indicative of the results to be expected for the year ending December 31, 2023 or for any other interim period or for any future period.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principles of Consolidation</b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements include the accounts of the Company and its subsidiary. Significant intercompany balances and transactions have been eliminated in consolidation.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GLUCOTRACK INC.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 68.05pt; text-align: justify; text-indent: -68.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A. Basis of Presentation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net Loss Per Common Stock</b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic net loss per Common Stock is computed by dividing the loss for the period applicable for holders of Common Stock and pre-funded warrants (after considering the effect of deemed dividend related to trigger of down round protection feature) dividend by the weighted average number of outstanding shares of Common Stock and shares of Common Stock to be issued upon exercise of pre-funded warrants (see Note 3A below) or shares of Common Stock to be issued upon achievement of performance milestone (see Note 3B below) during the period. Diluted loss per share gives effect to all potentially dilutive common shares outstanding during the period using the treasury stock method with respect to stock options and certain stock warrants. In computing diluted loss per share, the average stock price for the period is used in determining the number of Common Stock assumed to be purchased from the exercise of stock options or stock warrants. </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares to be issued upon exercise of all stock options and stock warrants have been excluded from the calculation of the diluted net loss per Common Stock for all the reported periods for which net loss was reported because the effect of the Common Stock issuable upon exercise of these instruments was anti-dilutive.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The net loss and the weighted average number of shares of Common Stock used in computing basic and diluted net loss per share for the period of three and nine months ended September 30, 2023 and 2022, is as follows:</span></td></tr> </table> <p style="margin-top: 0; margin-bottom: 0"> </p> <p id="xdx_899_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z1jnpyhC5CL4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_z0GrGgSm5VS" style="display: none">SCHEDULE OF ANTIDILUTIVE NET LOSS AND WEIGHTED AVERAGE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_490_20230701__20230930_zFZrrMi15bRc" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49B_20220701__20220930_zJq14X6nIAKl" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49E_20230101__20230930_zMRDdgqjZ7F1" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_493_20220101__20220930_z7sn6N8uOJt7" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><b> </b></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td colspan="5" style="border-bottom: Black 1.5pt solid; text-align: center"><b>US dollars in thousands<br/> (except share data)</b></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="text-align: center; margin-top: 0; margin-bottom: 0"><b>US dollars in thousands</b></p> <p style="text-align: center; margin-top: 0; margin-bottom: 0"><b>(except share data)</b></p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><b> </b></td> </tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><b> </b></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td colspan="5" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><b>Three-month period</b></p> <p style="margin-top: 0; margin-bottom: 0"><b>ended<br/> September 30,</b></p></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><b>Nine-month period</b></p> <p style="margin-top: 0; margin-bottom: 0"><b>ended<br/> September 30,</b></p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><b> </b></td> </tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><b> </b></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td colspan="5" style="border-bottom: Black 1.5pt solid; text-align: center"><b>(Unaudited)</b></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>(Unaudited)</b></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><b> </b></td> </tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><b> </b></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><b>2023</b></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><b>2022</b></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>2023</b></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><b> </b></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>2022</b></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><b> </b></td> </tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Numerator:</td><td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td> </tr> <tr id="xdx_40C_eus-gaap--NetIncomeLoss_iN_pn3n3_di_znrls8icMfT1" style="vertical-align: bottom; background-color: White"> <td style="width: 48%; text-align: left; padding-left: 10pt">Net loss</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">2,223</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">928</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,685</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,148</td><td style="width: 1%; text-align: left"> </td> </tr> <tr id="xdx_404_ecustom--DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature_pn3n3_zEKOYy4nwhC3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Deemed dividend related to trigger of down round protection feature (see Note 3A below)</td><td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0551">-</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0552">-</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">855</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0554">-</span></td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Net loss attributable to common stockholders</td><td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_90A_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_c20230701__20230930_zFTDUcj3yxZd" title="Net basic loss"><span id="xdx_903_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_c20230701__20230930_zZEkcmnxutf7" title="Net diluted loss">2,223</span></span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_901_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_c20220701__20220930_z5UNj3cLyWx1"><span id="xdx_90D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_c20220701__20220930_zgyXH0LFwnqe" title="Net diluted loss">928</span></span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_900_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_c20230101__20230930_zMh1gCmNbY76" title="Net basic loss"><span id="xdx_908_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_c20230101__20230930_zenTt4oUhBIg" title="Net diluted loss">5,540</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_c20220101__20220930_zWQo4Z7Oldbk" title="Net basic loss"><span id="xdx_906_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_c20220101__20220930_zQJJuRVC8NQ6" title="Net diluted loss">3,148</span></span></td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>Denominator:</td><td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Shares of Common Stock used in computing basic and diluted net loss per common stock</td><td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zvvUzbcknn" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zPCuDduXoOCe" title="Ordinary shares used in computing diluted net loss per common stock">20,892,193</span></span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zu5sEUUxAoeb" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zwDav1GfMM5f" title="Ordinary shares used in computing diluted net loss per common stock">15,473,521</span></span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zwXTpj81EBrk" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zo9ybq7bnnLi" title="Ordinary shares used in computing diluted net loss per common stock">18,792,950</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_z5u3xnxjAQS5" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zz2o8X5wmD7h" title="Ordinary shares used in computing diluted net loss per common stock">15,468,279</span></span></td><td style="text-align: left"> </td> </tr> <tr id="xdx_406_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_hus-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_znBMdvwMlOf8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Shares of Common Stock to be issued upon exercise of pre-funded warrants</td><td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0587">-</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,976,470</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,206,228</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0590">-</span></span></td><td style="text-align: left"> </td> </tr> <tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_z3wA5P3Zxj1l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Shares of Common Stock to be issued upon achievement of performance milestone</td><td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">100,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">33,456</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Basic and diluted net loss per common stock</td><td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_907_eus-gaap--EarningsPerShareBasic_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zL8Pf8rxO0J4" title="Basic net loss per common stock"><span id="xdx_907_eus-gaap--EarningsPerShareDiluted_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zytmV3sQdon3" title="Diluted net loss per common stock">(0.10</span></span></td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_902_eus-gaap--EarningsPerShareBasic_pid_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zcHS4b94fcP5" title="Basic net loss per common stock"><span id="xdx_902_eus-gaap--EarningsPerShareDiluted_pid_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zxUFdjZegsj4" title="Diluted net loss per common stock">(0.06</span></span></td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--EarningsPerShareBasic_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zKrVxnCydPYe" title="Basic net loss per common stock"><span id="xdx_903_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zn3MugNpctX9" title="Diluted net loss per common stock">(0.28</span></span></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_903_eus-gaap--EarningsPerShareBasic_pid_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zMFyAM4JX2A6" title="Basic net loss per common stock"><span id="xdx_903_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zkWA8MI1Kce7" title="Diluted net loss per common stock">(0.2</span></span></td><td style="text-align: left">)</td> </tr> </table> <p id="xdx_8AB_z2BsDtBMB8Ph" style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_899_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z1jnpyhC5CL4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_z0GrGgSm5VS" style="display: none">SCHEDULE OF ANTIDILUTIVE NET LOSS AND WEIGHTED AVERAGE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_490_20230701__20230930_zFZrrMi15bRc" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49B_20220701__20220930_zJq14X6nIAKl" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49E_20230101__20230930_zMRDdgqjZ7F1" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2023</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_493_20220101__20220930_z7sn6N8uOJt7" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2022</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><b> </b></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td colspan="5" style="border-bottom: Black 1.5pt solid; text-align: center"><b>US dollars in thousands<br/> (except share data)</b></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="text-align: center; margin-top: 0; margin-bottom: 0"><b>US dollars in thousands</b></p> <p style="text-align: center; margin-top: 0; margin-bottom: 0"><b>(except share data)</b></p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><b> </b></td> </tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><b> </b></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td colspan="5" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><b>Three-month period</b></p> <p style="margin-top: 0; margin-bottom: 0"><b>ended<br/> September 30,</b></p></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><b>Nine-month period</b></p> <p style="margin-top: 0; margin-bottom: 0"><b>ended<br/> September 30,</b></p></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><b> </b></td> </tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><b> </b></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td colspan="5" style="border-bottom: Black 1.5pt solid; text-align: center"><b>(Unaudited)</b></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>(Unaudited)</b></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><b> </b></td> </tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><b> </b></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><b>2023</b></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><b>2022</b></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>2023</b></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><b> </b></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>2022</b></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><b> </b></td> </tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Numerator:</td><td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td> </tr> <tr id="xdx_40C_eus-gaap--NetIncomeLoss_iN_pn3n3_di_znrls8icMfT1" style="vertical-align: bottom; background-color: White"> <td style="width: 48%; text-align: left; padding-left: 10pt">Net loss</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">2,223</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td> <td style="width: 9%; text-align: right">928</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,685</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,148</td><td style="width: 1%; text-align: left"> </td> </tr> <tr id="xdx_404_ecustom--DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature_pn3n3_zEKOYy4nwhC3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Deemed dividend related to trigger of down round protection feature (see Note 3A below)</td><td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0551">-</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0552">-</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">855</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0554">-</span></td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Net loss attributable to common stockholders</td><td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_90A_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_c20230701__20230930_zFTDUcj3yxZd" title="Net basic loss"><span id="xdx_903_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_c20230701__20230930_zZEkcmnxutf7" title="Net diluted loss">2,223</span></span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_901_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_c20220701__20220930_z5UNj3cLyWx1"><span id="xdx_90D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_c20220701__20220930_zgyXH0LFwnqe" title="Net diluted loss">928</span></span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_900_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_c20230101__20230930_zMh1gCmNbY76" title="Net basic loss"><span id="xdx_908_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_c20230101__20230930_zenTt4oUhBIg" title="Net diluted loss">5,540</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90A_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_c20220101__20220930_zWQo4Z7Oldbk" title="Net basic loss"><span id="xdx_906_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pn3n3_c20220101__20220930_zQJJuRVC8NQ6" title="Net diluted loss">3,148</span></span></td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>Denominator:</td><td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Shares of Common Stock used in computing basic and diluted net loss per common stock</td><td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zvvUzbcknn" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zPCuDduXoOCe" title="Ordinary shares used in computing diluted net loss per common stock">20,892,193</span></span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zu5sEUUxAoeb" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zwDav1GfMM5f" title="Ordinary shares used in computing diluted net loss per common stock">15,473,521</span></span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zwXTpj81EBrk" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zo9ybq7bnnLi" title="Ordinary shares used in computing diluted net loss per common stock">18,792,950</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_z5u3xnxjAQS5" title="Ordinary shares used in computing basic net loss per common stock"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_fKCop_zz2o8X5wmD7h" title="Ordinary shares used in computing diluted net loss per common stock">15,468,279</span></span></td><td style="text-align: left"> </td> </tr> <tr id="xdx_406_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_hus-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_znBMdvwMlOf8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Shares of Common Stock to be issued upon exercise of pre-funded warrants</td><td> </td> <td style="text-align: left"> </td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0587">-</span></td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">1,976,470</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,206,228</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0590">-</span></span></td><td style="text-align: left"> </td> </tr> <tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_z3wA5P3Zxj1l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Shares of Common Stock to be issued upon achievement of performance milestone</td><td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right">100,000</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td><td style="text-align: right">33,456</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Basic and diluted net loss per common stock</td><td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_907_eus-gaap--EarningsPerShareBasic_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zL8Pf8rxO0J4" title="Basic net loss per common stock"><span id="xdx_907_eus-gaap--EarningsPerShareDiluted_pid_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zytmV3sQdon3" title="Diluted net loss per common stock">(0.10</span></span></td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left">$</td> <td style="text-align: right"><span id="xdx_902_eus-gaap--EarningsPerShareBasic_pid_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zcHS4b94fcP5" title="Basic net loss per common stock"><span id="xdx_902_eus-gaap--EarningsPerShareDiluted_pid_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zxUFdjZegsj4" title="Diluted net loss per common stock">(0.06</span></span></td> <td style="text-align: left">)</td> <td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--EarningsPerShareBasic_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zKrVxnCydPYe" title="Basic net loss per common stock"><span id="xdx_903_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zn3MugNpctX9" title="Diluted net loss per common stock">(0.28</span></span></td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_903_eus-gaap--EarningsPerShareBasic_pid_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zMFyAM4JX2A6" title="Basic net loss per common stock"><span id="xdx_903_eus-gaap--EarningsPerShareDiluted_pid_c20220101__20220930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zkWA8MI1Kce7" title="Diluted net loss per common stock">(0.2</span></span></td><td style="text-align: left">)</td> </tr> </table> -2223000 -928000 -4685000 -3148000 855000 2223000 2223000 928000 928000 5540000 5540000 3148000 3148000 20892193 20892193 15473521 15473521 18792950 18792950 15468279 15468279 1976470 1206228 100000 33456 -0.10 -0.10 -0.06 -0.06 -0.28 -0.28 -0.2 -0.2 <p id="xdx_80F_ecustom--SignificantTransactionsTextBlock_zxs8M1CH7P5d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 3 - <span id="xdx_820_zkEub3xY707j">SIGNIFICANT TRANSACTIONS</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>A.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Completion of underwritten U.S. public offering</b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On April 13, 2023, the Company completed an underwritten public offering under which <span id="xdx_907_eus-gaap--CommonStockCallOrExerciseFeatures_c20230413__20230413_zUOJykixdol9" title="Description of common stock">the Company received gross proceeds of approximately $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn6n6_c20230413__20230413_zkpxc17uSr6d" title="Gross proceeds">10</span> million for issuance of (i) <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230413__20230413__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0tL46Gix5ee" title="Common stock shares">5,376,472</span> shares of common stock and (ii) <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230413__20230413__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zs19WS8NP4a9" title="Common stock shares">1,976,470</span> pre-funded warrants at a price to the public of $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230413__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zuWRXtM2cc5d" title="Share price">1.36</span> per share. The pre-funded warrants are exercisable for the same number of shares of common stock and may be exercised at any time until exercised in full at an exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230413__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_ziqreeGl0BB5" title="Exercise price">0.001</span>.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon satisfaction of customary closing conditions, the closing date of the above underwritten public offering was April 17, 2023 (the “Closing Date”).</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company received substantially all the pre-funded warrant’s proceeds upfront (without any conditions) as part of the pre-funded warrant’s purchase price and in return the Company is obligated to issue fixed number of shares of common stock to the holders. Thus, pre-funded warrants were accounted for and were classified as additional paid-in capital as part of the Company’s stockholders’ equity.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total incremental and direct issuance costs amounted to $<span id="xdx_909_eus-gaap--PaymentsOfStockIssuanceCosts_pn3n3_c20230413__20230413_zOKnbROT1Ov4" title="Incremental and direct issuance costs">1,270</span> thousand. These expenses were deducted from additional paid-in capital as they were allocated to shares of Common Stock and pre-funded warrants.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon closing of underwritten U.S. public offering, a down round protection feature of certain warrants granted in previous years to service providers was triggered by the way of reduction of their exercise price from a price in a range of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230413__srt--RangeAxis__srt--MinimumMember_z9ZjqSfMB957" title="Exercise price">3.35</span>-$<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230413__srt--RangeAxis__srt--MaximumMember_zONG12D8QJsg" title="Exercise price">70.20</span> to a price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230413_zMsbEuq0EVwl" title="Exercise price">1.36</span> which represented the above public offering price. Such reduction was accounted for as deemed dividend estimated at total amount of $<span id="xdx_902_eus-gaap--AdditionalPaidInCapital_iI_pn3n3_c20230413_z8BTHObwHJ1j" title="Additional paid in capital">855</span> thousand which was recorded as part of the additional paid-in capital versus increase of accumulated deficit. Regarding the effect of the loss per share, see also Note 2.A.3. above.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>B.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intellectual Property Purchase Agreement</b> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the middle of June 2023, the Company achieved the first performance milestone out of the five performance milestones outlined in the Intellectual Property Purchase Agreement (the “Agreement”) executed between the Company and Paul Goode, which is the Company’s Chief Executive Officer (the “Seller”) as October 7, 2022 (the “Closing Date”). As a result, upon the date of fulfillment of the performance milestone the Company is committed to issue <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--IntellectualPropertyPurchaseAgreementMember_zchZKthdsEog" title="Number of common shares issued">100,000</span> restricted shares to the Seller. During the periods of three and nine months ended September 30, 2023, the Company recorded stock-based compensation expenses of $<span id="xdx_90F_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20230701__20230930__us-gaap--TypeOfArrangementAxis__custom--IntellectualPropertyPurchaseAgreementMember_zJDuzgSd3Vqb" title="Share based compensation">0</span> and $<span id="xdx_900_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--IntellectualPropertyPurchaseAgreementMember_z6z79Y2YodRc" title="Share based compensation">131</span> thousand, respectively, which represents the quoted price of its Common Stock at the Closing Date, after taking into consideration a discount for lack of marketability at a rate of <span id="xdx_902_ecustom--DiscountRate_iI_pid_dp_uPure_c20230701__20230930__us-gaap--TypeOfArrangementAxis__custom--IntellectualPropertyPurchaseAgreementMember_zkKtz4EFrojh" title="Discount rate"><span id="xdx_903_ecustom--DiscountRate_iI_pid_dp_uPure_c20230101__20230930__us-gaap--TypeOfArrangementAxis__custom--IntellectualPropertyPurchaseAgreementMember_zoRoLsfcEY2j" title="Discount rate">30.4</span></span>% over a restriction period of 1-year. As of September 30, 2023, achievement of all other performance milestones was not considered probable and thus no stock-based compensation expenses were recorded with respect to thereof.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>C.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard</b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 26, 2023, the Company received a letter from Nasdaq that it no longer complies with Rule 5550(a)(2) of Nasdaq’s Listing Rules (the “Rules”) which require listed securities to maintain a minimum bid price of $<span id="xdx_909_eus-gaap--SharePrice_iI_pid_c20230526_zgqTJfSdBWAc" title="Minimum bid price">1</span> per share. However, the Rules provide the Company a compliance period of 180-days to regain compliance under which if at any time during 180-days period the closing bid price of the Company’s security is at least $<span id="xdx_902_eus-gaap--SharePrice_iI_pid_c20230526_zDHmzcxyY5sj" title="Minimum bid price">1</span> for a minimum of ten consecutive business days, Nasdaq will provide the Company written confirmation of compliance and this matter will be closed. In the event the Company does not regain compliance by the 180th day, the Company may be eligible for additional time to regain compliance or may face delisting.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> the Company received gross proceeds of approximately $10 million for issuance of (i) 5,376,472 shares of common stock and (ii) 1,976,470 pre-funded warrants at a price to the public of $1.36 per share. The pre-funded warrants are exercisable for the same number of shares of common stock and may be exercised at any time until exercised in full at an exercise price of $0.001. 10000000 5376472 1976470 1.36 0.001 1270000 3.35 70.20 1.36 855000 100000 0 131000 0.304 0.304 1 1 <p id="xdx_808_eus-gaap--SubsequentEventsTextBlock_zoMjFvpenmOd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 4 - <span id="xdx_820_zBf0kfTu3j1b">SUBSEQUENT EVENTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the condensed interim consolidated financial statements were issued November 14, 2023. Based upon this review, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements.</span></p> Represents amount lower than $1. EXCEL 27 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 29 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 30 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 75 113 1 true 9 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://glucotrack.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://glucotrack.com/role/BalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://glucotrack.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited) Sheet http://glucotrack.com/role/StatementOfChangesInStockholdersEquity Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://glucotrack.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - GENERAL Sheet http://glucotrack.com/role/General GENERAL Notes 7 false false R8.htm 00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://glucotrack.com/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 00000009 - Disclosure - SIGNIFICANT TRANSACTIONS Sheet http://glucotrack.com/role/SignificantTransactions SIGNIFICANT TRANSACTIONS Notes 9 false false R10.htm 00000010 - Disclosure - SUBSEQUENT EVENTS Sheet http://glucotrack.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 10 false false R11.htm 00000011 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 11 false false R12.htm 00000012 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://glucotrack.com/role/SummaryOfSignificantAccountingPolicies 12 false false R13.htm 00000013 - Disclosure - GENERAL (Details Narrative) Sheet http://glucotrack.com/role/GeneralDetailsNarrative GENERAL (Details Narrative) Details http://glucotrack.com/role/General 13 false false R14.htm 00000014 - Disclosure - SCHEDULE OF ANTIDILUTIVE NET LOSS AND WEIGHTED AVERAGE (Details) Sheet http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails SCHEDULE OF ANTIDILUTIVE NET LOSS AND WEIGHTED AVERAGE (Details) Details 14 false false R15.htm 00000015 - Disclosure - SIGNIFICANT TRANSACTIONS (Details Narrative) Sheet http://glucotrack.com/role/SignificantTransactionsDetailsNarrative SIGNIFICANT TRANSACTIONS (Details Narrative) Details http://glucotrack.com/role/SignificantTransactions 15 false false All Reports Book All Reports form10-q.htm gctk-20230930.xsd gctk-20230930_cal.xml gctk-20230930_def.xml gctk-20230930_lab.xml gctk-20230930_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 32 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form10-q.htm": { "nsprefix": "GCTK", "nsuri": "http://glucotrack.com/20230930", "dts": { "inline": { "local": [ "form10-q.htm" ] }, "schema": { "local": [ "gctk-20230930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "calculationLink": { "local": [ "gctk-20230930_cal.xml" ] }, "definitionLink": { "local": [ "gctk-20230930_def.xml" ] }, "labelLink": { "local": [ "gctk-20230930_lab.xml" ] }, "presentationLink": { "local": [ "gctk-20230930_pre.xml" ] } }, "keyStandard": 102, "keyCustom": 11, "axisStandard": 3, "axisCustom": 0, "memberStandard": 6, "memberCustom": 3, "hidden": { "total": 95, "http://xbrl.sec.gov/dei/2023": 4, "http://glucotrack.com/20230930": 18, "http://fasb.org/us-gaap/2023": 73 }, "contextCount": 75, "entityCount": 1, "segmentCount": 9, "elementCount": 179, "unitCount": 4, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 358, "http://xbrl.sec.gov/dei/2023": 30 }, "report": { "R1": { "role": "http://glucotrack.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R2": { "role": "http://glucotrack.com/role/BalanceSheets", "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R3": { "role": "http://glucotrack.com/role/BalanceSheetsParenthetical", "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R4": { "role": "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss", "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2023-07-012023-09-30", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-012023-09-30", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R5": { "role": "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity", "longName": "00000005 - Statement - Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited)", "shortName": "Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R6": { "role": "http://glucotrack.com/role/StatementsOfCashFlows", "longName": "00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R7": { "role": "http://glucotrack.com/role/General", "longName": "00000007 - Disclosure - GENERAL", "shortName": "GENERAL", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R8": { "role": "http://glucotrack.com/role/SummaryOfSignificantAccountingPolicies", "longName": "00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R9": { "role": "http://glucotrack.com/role/SignificantTransactions", "longName": "00000009 - Disclosure - SIGNIFICANT TRANSACTIONS", "shortName": "SIGNIFICANT TRANSACTIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "GCTK:SignificantTransactionsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "GCTK:SignificantTransactionsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R10": { "role": "http://glucotrack.com/role/SubsequentEvents", "longName": "00000010 - Disclosure - SUBSEQUENT EVENTS", "shortName": "SUBSEQUENT EVENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R11": { "role": "http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "longName": "00000011 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "11", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R12": { "role": "http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesTables", "longName": "00000012 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "12", "firstAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R13": { "role": "http://glucotrack.com/role/GeneralDetailsNarrative", "longName": "00000013 - Disclosure - GENERAL (Details Narrative)", "shortName": "GENERAL (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "13", "firstAnchor": { "contextRef": "AsOf2023-09-30", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R14": { "role": "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails", "longName": "00000014 - Disclosure - SCHEDULE OF ANTIDILUTIVE NET LOSS AND WEIGHTED AVERAGE (Details)", "shortName": "SCHEDULE OF ANTIDILUTIVE NET LOSS AND WEIGHTED AVERAGE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "14", "firstAnchor": { "contextRef": "From2023-07-012023-09-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "GCTK:DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R15": { "role": "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative", "longName": "00000015 - Disclosure - SIGNIFICANT TRANSACTIONS (Details Narrative)", "shortName": "SIGNIFICANT TRANSACTIONS (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "15", "firstAnchor": { "contextRef": "From2023-04-132023-04-13", "name": "us-gaap:CommonStockCallOrExerciseFeatures", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "GCTK:SignificantTransactionsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-04-132023-04-13", "name": "us-gaap:CommonStockCallOrExerciseFeatures", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "GCTK:SignificantTransactionsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } } }, "tag": { "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r281" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r280" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://glucotrack.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL ASSETS", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r51", "r60", "r79", "r108", "r110", "r112", "r114", "r121", "r122", "r123", "r124", "r125", "r126", "r127", "r128", "r129", "r146", "r148", "r159", "r177", "r222", "r265", "r277", "r310", "r311", "r316" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Operating loss", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r108", "r109", "r111", "r113", "r261" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://glucotrack.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r33" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Comprehensive loss for the period", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r19", "r66", "r68", "r73", "r174", "r185" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r280" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r280" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "SCHEDULE OF ANTIDILUTIVE NET LOSS AND WEIGHTED AVERAGE", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r22" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "presentation": [ "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails" ], "lang": { "en-us": { "role": { "label": "Net diluted loss", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r75", "r95", "r97", "r98", "r99", "r100", "r102", "r105" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://glucotrack.com/role/General" ], "lang": { "en-us": { "role": { "label": "GENERAL", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r27", "r50", "r194", "r195" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of Presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r289", "r291", "r292" ] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharePrice", "presentation": [ "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Minimum bid price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r290" ] }, "GCTK_IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors": { "xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20230930", "localname": "IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors", "crdr": "debit", "calculation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://glucotrack.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Issuance of restricted shares as compensation towards directors", "documentation": "Issuance of restricted shares as compensation to the board of directors.", "label": "IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://glucotrack.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "auth_ref": [] }, "GCTK_LinkageDifferenceOnPrincipalOfLoansFromStockholders": { "xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20230930", "localname": "LinkageDifferenceOnPrincipalOfLoansFromStockholders", "crdr": "debit", "calculation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://glucotrack.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Linkage difference on principal of loans from stockholders", "documentation": "Linkage difference on principal of loans from stockholders ." } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://glucotrack.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r14", "r58", "r79", "r114", "r121", "r122", "r123", "r124", "r125", "r126", "r127", "r128", "r129", "r147", "r148", "r149", "r159", "r265", "r310", "r316", "r317" ] }, "GCTK_DeemedDividendUponTriggerOfDownRoundProtection": { "xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20230930", "localname": "DeemedDividendUponTriggerOfDownRoundProtection", "crdr": "credit", "presentation": [ "http://glucotrack.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Deemed dividend upon trigger of down round protection", "documentation": "Deemed dividend upon trigger of down round protection." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r293" ] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesNoncurrentAbstract", "presentation": [ "http://glucotrack.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Non-current liabilities" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r291" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://glucotrack.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r33" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://glucotrack.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r76" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r282" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://glucotrack.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r76" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://glucotrack.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r283" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://glucotrack.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r44", "r45", "r46" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://glucotrack.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current liabilities" } } }, "auth_ref": [] }, "GCTK_ProceedsReceivedFromUnderwrittenPublicOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20230930", "localname": "ProceedsReceivedFromUnderwrittenPublicOffering", "crdr": "debit", "calculation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://glucotrack.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Net proceeds received from underwritten U.S. public offering", "documentation": "Proceeds received from underwritten public offering.", "label": "ProceedsReceivedFromUnderwrittenPublicOffering" } } }, "auth_ref": [] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://glucotrack.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common Stock of $ 0.001 par value (\u201cCommon Stock\u201d): 500,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 20,892,193 and 15,500,730 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r33", "r178", "r265" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://glucotrack.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES" } } }, "auth_ref": [] }, "GCTK_DisclosureSignificantTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://glucotrack.com/20230930", "localname": "DisclosureSignificantTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Significant Transactions" } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r291" ] }, "GCTK_SignificantTransactionsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://glucotrack.com/20230930", "localname": "SignificantTransactionsTextBlock", "presentation": [ "http://glucotrack.com/role/SignificantTransactions" ], "lang": { "en-us": { "role": { "label": "SIGNIFICANT TRANSACTIONS", "documentation": "Significant Transactions [Text Block]" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r280" ] }, "GCTK_DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature": { "xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20230930", "localname": "DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature", "crdr": "credit", "presentation": [ "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails" ], "lang": { "en-us": { "role": { "label": "Deemed dividend related to trigger of down round protection feature (see Note 3A below)", "documentation": "Deemed dividend related to trigger of down round protection feature." } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://glucotrack.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r33", "r210" ] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://glucotrack.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other current liabilities", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r13", "r265" ] }, "GCTK_DiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://glucotrack.com/20230930", "localname": "DiscountRate", "presentation": [ "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Discount rate", "documentation": "Discount rate." } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://glucotrack.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r8", "r33", "r210", "r228", "r327", "r328" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r287" ] }, "us-gaap_LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://glucotrack.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total non-current liabilities", "label": "Liabilities, Noncurrent", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r10", "r28", "r29", "r30", "r31", "r79", "r114", "r121", "r122", "r123", "r124", "r125", "r126", "r127", "r128", "r129", "r147", "r148", "r149", "r159", "r310", "r316", "r317" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r294" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://glucotrack.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Loans from stockholders", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r291" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r297" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r278" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://glucotrack.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r4" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative", "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r267", "r268", "r269", "r271", "r272", "r273", "r274", "r305", "r306", "r313", "r325", "r327" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r295" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r145" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "crdr": "credit", "presentation": [ "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Issuance of restricted shares as compensation towards directors", "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period." } } }, "auth_ref": [ "r8", "r32", "r33", "r49" ] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfArrangementAxis", "presentation": [ "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r145" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r117", "r118", "r119", "r120", "r132", "r133", "r136", "r137", "r138", "r170", "r171", "r187", "r201", "r202", "r250", "r251", "r252", "r253", "r254", "r256", "r257", "r262", "r263", "r264", "r266", "r269", "r309", "r312", "r319", "r320", "r321", "r322", "r323" ] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": [ "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r25", "r32", "r33", "r49" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://glucotrack.com/role/BalanceSheets", "http://glucotrack.com/role/GeneralDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "negatedLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r35", "r49", "r180", "r191", "r193", "r198", "r211", "r265" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "presentation": [ "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails" ], "lang": { "en-us": { "role": { "label": "Net basic loss", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r75", "r85", "r86", "r87", "r88", "r93", "r94", "r102", "r105", "r108", "r109", "r111", "r113", "r261" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Net proceeds received from underwritten U.S. public offering", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r8", "r32", "r33", "r49", "r199", "r247", "r255", "r276" ] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://glucotrack.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r57", "r63", "r79", "r114", "r121", "r122", "r123", "r124", "r125", "r126", "r127", "r128", "r129", "r146", "r148", "r159", "r265", "r310", "r311", "r316" ] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesIssuedPricePerShare", "presentation": [ "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share price", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": [ "r117", "r118", "r119", "r120", "r133", "r171", "r187", "r201", "r202", "r250", "r251", "r252", "r253", "r254", "r256", "r257", "r262", "r263", "r264", "r266", "r312", "r318", "r319", "r320", "r321", "r322", "r323" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r292" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r279" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" ], "auth_ref": [ "r117", "r118", "r119", "r120", "r132", "r133", "r136", "r137", "r138", "r170", "r171", "r187", "r201", "r202", "r250", "r251", "r252", "r253", "r254", "r256", "r257", "r262", "r263", "r264", "r266", "r269", "r309", "r312", "r319", "r320", "r321", "r322", "r323" ] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails", "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Basic net loss per common stock", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r74", "r85", "r86", "r87", "r88", "r89", "r93", "r96", "r103", "r104", "r105", "r106", "r157", "r158", "r175", "r186", "r259" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": [ "r117", "r118", "r119", "r120", "r133", "r171", "r187", "r201", "r202", "r250", "r251", "r252", "r253", "r254", "r256", "r257", "r262", "r263", "r264", "r266", "r312", "r318", "r319", "r320", "r321", "r322", "r323" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r292" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://glucotrack.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current assets" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://glucotrack.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails", "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity", "http://glucotrack.com/role/StatementsOfCashFlows", "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Net Loss", "label": "Loss for the period", "negatedLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r40", "r46", "r53", "r56", "r64", "r67", "r71", "r79", "r83", "r85", "r86", "r87", "r88", "r91", "r92", "r101", "r108", "r109", "r111", "r113", "r114", "r121", "r122", "r123", "r124", "r125", "r126", "r127", "r128", "r129", "r158", "r159", "r183", "r230", "r245", "r246", "r261", "r275", "r310" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r291" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross", "crdr": "credit", "presentation": [ "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock-based compensation", "label": "Shares Issued, Value, Share-Based Payment Arrangement, before Forfeiture", "documentation": "Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [] }, "us-gaap_EmployeeBenefitsAndShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeBenefitsAndShareBasedCompensation", "crdr": "debit", "presentation": [ "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share based compensation", "documentation": "Amount of expense for employee benefit and equity-based compensation." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails", "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Weighted average number of common stock outstanding used in computing basic net loss per share", "verboseLabel": "Ordinary shares used in computing basic net loss per common stock", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r93", "r105" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails", "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative", "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r80", "r81", "r82", "r107", "r172", "r196", "r200", "r203", "r204", "r205", "r206", "r207", "r208", "r210", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r223", "r224", "r225", "r226", "r227", "r229", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r247", "r270" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://glucotrack.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r34" ] }, "us-gaap_CommonStockCallOrExerciseFeatures": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockCallOrExerciseFeatures", "presentation": [ "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Description of common stock", "documentation": "Describe the call and/or exercise rights, prices and dates of common stock." } } }, "auth_ref": [ "r24", "r33" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://glucotrack.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r12", "r79", "r114", "r121", "r122", "r123", "r124", "r125", "r126", "r127", "r128", "r129", "r147", "r148", "r149", "r159", "r209", "r260", "r277", "r310", "r316", "r317" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r296" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": [ "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Gross proceeds", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r3" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r288" ] }, "us-gaap_LiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAbstract", "presentation": [ "http://glucotrack.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://glucotrack.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accumulated other comprehensive income", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r17", "r18", "r39", "r61", "r179", "r192", "r193" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income:" } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r286" ] }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceInitialPublicOffering", "crdr": "debit", "presentation": [ "http://glucotrack.com/role/GeneralDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Net proceeds", "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r285" ] }, "us-gaap_OtherNonoperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingExpense", "crdr": "debit", "calculation": { "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Other expenses", "documentation": "Amount of expense related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r42" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://glucotrack.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r43" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://glucotrack.com/role/BalanceSheets", "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r33", "r36", "r37", "r48", "r212", "r228", "r248", "r249", "r265", "r277", "r304", "r308", "r314", "r327" ] }, "us-gaap_RestrictedCashNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashNoncurrent", "crdr": "debit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://glucotrack.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Restricted cash", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r54", "r298", "r303" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://glucotrack.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r38", "r52", "r181", "r265", "r304", "r308", "r314" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Research and development", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r26", "r142", "r324" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r284" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://glucotrack.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r6", "r176", "r182", "r265" ] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Exercise price", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r130" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://glucotrack.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other current assets", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r62", "r265" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation, shares", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r134" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://glucotrack.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://glucotrack.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r21", "r59", "r258" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://glucotrack.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Change in cash, cash equivalents, and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r0", "r44" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails", "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Weighted average number of common stock outstanding used in computing diluted net loss per share", "verboseLabel": "Ordinary shares used in computing diluted net loss per common stock", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r95", "r105" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "calculation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://glucotrack.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Effect of exchange rate changes on cash and cash equivalents, and restricted cash", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r315" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://glucotrack.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of the period", "periodEndLabel": "Cash, cash equivalents, and restricted cash, end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r21", "r44", "r77" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://glucotrack.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Non-cash financing activities" } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r292" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "presentation": [ "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Additional paid in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r34", "r265", "r326" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails", "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Diluted net loss per common stock", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r74", "r85", "r86", "r87", "r88", "r89", "r96", "r103", "r104", "r105", "r106", "r157", "r158", "r175", "r186", "r259" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r280" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r139", "r140", "r141", "r199", "r305", "r306", "r307", "r313", "r327" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative", "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Net proceeds received from underwritten U.S. public offering, shares", "verboseLabel": "Number of common shares issued", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r8", "r32", "r33", "r49", "r197", "r247", "r255" ] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r41", "r232" ] }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherCurrentAssets", "crdr": "credit", "calculation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://glucotrack.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Increase in other current assets", "label": "Increase (Decrease) in Other Current Assets", "documentation": "Amount of increase (decrease) in current assets classified as other." } } }, "auth_ref": [ "r302" ] }, "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherCurrentLiabilities", "crdr": "debit", "calculation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://glucotrack.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in other current liabilities", "documentation": "Amount of increase (decrease) in current liabilities classified as other." } } }, "auth_ref": [ "r302" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://glucotrack.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r11", "r265" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails", "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative", "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r8", "r16", "r55", "r69", "r70", "r71", "r80", "r81", "r82", "r84", "r90", "r92", "r107", "r115", "r116", "r131", "r139", "r140", "r141", "r143", "r144", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r160", "r162", "r163", "r164", "r165", "r166", "r167", "r188", "r189", "r190", "r199", "r247" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "presentation": [ "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Issuance of restricted shares as compensation towards directors, shares", "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards." } } }, "auth_ref": [ "r8", "r49" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r55", "r80", "r81", "r82", "r84", "r90", "r92", "r115", "r116", "r139", "r140", "r141", "r143", "r144", "r150", "r152", "r153", "r155", "r156", "r188", "r190", "r199", "r327" ] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance, shares", "periodEndLabel": "Balance, shares", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://glucotrack.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r5", "r23" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails" ], "lang": { "en-us": { "role": { "label": "Shares of Common Stock to be issued upon achievement of performance milestone", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r8", "r32", "r33", "r49", "r135" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://glucotrack.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "label": "SUBSEQUENT EVENTS", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r168", "r169" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails", "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative", "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r8", "r55", "r69", "r70", "r71", "r80", "r81", "r82", "r84", "r90", "r92", "r107", "r115", "r116", "r131", "r139", "r140", "r141", "r143", "r144", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r160", "r162", "r163", "r164", "r165", "r166", "r167", "r188", "r189", "r190", "r199", "r247" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "negatedLabel": "Foreign currency translation adjustment", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r280" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": [ "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r8", "r9", "r65", "r68", "r72", "r160", "r161", "r166", "r173", "r184", "r299", "r300" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r1", "r7", "r18", "r151", "r154", "r167", "r188", "r189", "r299", "r300", "r301", "r305", "r306", "r307" ] }, "GCTK_ReceiptsOnAccountOfSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://glucotrack.com/20230930", "localname": "ReceiptsOnAccountOfSharesMember", "presentation": [ "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Receipts on Account of Shares [Member]", "documentation": "Receipts on Account of Shares [Member]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsPayableTrade": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableTrade", "crdr": "debit", "calculation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://glucotrack.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase in accounts payable", "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services." } } }, "auth_ref": [ "r4" ] }, "GCTK_StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross": { "xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20230930", "localname": "StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross", "crdr": "credit", "presentation": [ "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Restricted shares to be issued as compensation towards directors", "documentation": "Stock to be issued during period value restricted stock award gross." } } }, "auth_ref": [] }, "GCTK_AdjustmentsToAdditionalPaidInCapitalDeemedDividendResultedFromTriggerOfDownRoundProtectionFeatureOfCertainWarrantsGranted": { "xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20230930", "localname": "AdjustmentsToAdditionalPaidInCapitalDeemedDividendResultedFromTriggerOfDownRoundProtectionFeatureOfCertainWarrantsGranted", "crdr": "credit", "presentation": [ "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Deemed dividend resulted from trigger of down round protection feature of certain warrants granted", "documentation": "Adjustments to additional paid in capital deemed dividend resulted from trigger of down round protection feature of certain warrants granted." } } }, "auth_ref": [] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": [ "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Incremental and direct issuance costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": [ "r20" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://glucotrack.com/role/SummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r47", "r78" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://glucotrack.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 equity" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://glucotrack.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Changes in assets and liabilities:" } } }, "auth_ref": [] }, "GCTK_PrefundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://glucotrack.com/20230930", "localname": "PrefundedWarrantsMember", "presentation": [ "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails", "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Prefunded Warrants [Member]", "documentation": "Prefunded warrants member." } } }, "auth_ref": [] }, "GCTK_FinancingIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20230930", "localname": "FinancingIncomeExpenseNet", "crdr": "credit", "calculation": { "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "negatedLabel": "Finance expenses (income), net", "documentation": "Financing income expense net.", "label": "FinancingIncomeExpenseNet" } } }, "auth_ref": [] }, "GCTK_IntellectualPropertyPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://glucotrack.com/20230930", "localname": "IntellectualPropertyPurchaseAgreementMember", "presentation": [ "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Intellectual Property Purchase Agreement [Member]", "documentation": "Intellectual Property Purchase Agreement [Member]" } } }, "auth_ref": [] }, "GCTK_ReceiptsOnAccountOfShares": { "xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20230930", "localname": "ReceiptsOnAccountOfShares", "crdr": "credit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://glucotrack.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Receipts on account of shares", "documentation": "Receipts on account of shares." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://glucotrack.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r280" ] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails", "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative", "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r80", "r81", "r82", "r107", "r172", "r196", "r200", "r203", "r204", "r205", "r206", "r207", "r208", "r210", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r223", "r224", "r225", "r226", "r227", "r229", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r247", "r270" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r54": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210", "Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5" }, "r55": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r56": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r57": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r58": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r59": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r61": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r62": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r63": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r64": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r65": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r66": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r67": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r68": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r258": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r260": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r261": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r262": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r263": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r264": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r265": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r266": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r267": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r268": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r269": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r270": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r271": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r272": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r273": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r274": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r275": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r276": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r277": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r278": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r279": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r280": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r281": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r282": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r283": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r284": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r285": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r286": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r287": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r288": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r289": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r290": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r291": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r292": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r293": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r295": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r296": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r297": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r298": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r299": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r300": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r301": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r302": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r303": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r304": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r305": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r306": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r307": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r308": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r309": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r310": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r311": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r312": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r313": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r314": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r315": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r316": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r317": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r318": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r319": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r320": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r321": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r322": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r323": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r324": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r325": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r326": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r327": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r328": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 33 0001493152-23-040961-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-040961-xbrl.zip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end